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A B S T R A C T
Despite many high-profile successes, recombinant membrane protein production remains a technical challenge;
it is still the case that many fewer membrane protein structures have been published than those of soluble
proteins. However, progress is being made because empirical methods have been developed to produce the
required quantity and quality of these challenging targets. This review focuses on the microbial expression
systems that are a key source of recombinant prokaryotic and eukaryotic membrane proteins for structural
studies. We provide an overview of the host strains, tags and promoters that, in our experience, are most likely to
yield protein suitable for structural and functional characterization. We also catalogue the detergents used for
solubilization and crystallization studies of these proteins. Here, we emphasize a combination of practical
methods, not necessarily high-throughput, which can be implemented in any laboratory equipped for re-
combinant DNA technology and microbial cell culture.
1. Recombinant membrane protein production in microbes
Few membrane proteins are naturally abundant in their native
membranes; in order to characterize them biophysically and bio-
chemically, recombination of their genes with more efficient promoters
and regulators of expression are required [1]. Unsurprisingly, the few
naturally-abundant membrane proteins (including mammalian and
bacterial rhodopsins, aquaporins and complexes involved in respiration
and photosynthesis) were amongst the first to have their crystal-
lographic structures solved: the first high-resolution structure of a
membrane protein was that of the photosynthetic reaction centre from
Blastochloris viridis published in 1995 [2]. In 1998, the first recombinant
membrane protein structures were published: those of the prokaryotic
proteins MscL [3] and KcsA [4], both produced in Escherichia coli. The
first structures of recombinant mammalian membrane proteins were
solved in 2005 using protein that had been produced in yeast cells: the
rabbit Ca2+-ATPase, SERCA1a, was produced in Saccharomyces cerevi-
siae [5] and the rat voltage-dependent potassium ion channel, Kv1.2
was produced in Pichia pastoris [6]. These early results established
microbes as efficient and effective host systems for synthesizing mem-
brane proteins.
While baculovirus-infected insect cells and mammalian cell-lines
have been used very successfully for both prokaryotic and eukaryotic
membrane protein production [1], we note that microbes have re-
mained a consistently-popular choice because they are quick, easy and
cheap to culture and they can produce high-quality protein suitable for
subsequent study. In November 2017, Stephen White’s database
(blanco.biomol.uci.edu/mpstruc/) recorded that almost a third (31%)
of all membrane protein coordinate files deposited in the Protein Data
Bank (www.rcsb.org/pdb/home/home.do; PDB) were derived from
recombinant proteins; notably, 71% of all unique structures were de-
rived from microbial sources. Of these, 64% were produced in E. coli,
4% in P. pastoris and 3% in S. cerevisiae.
This review focuses on current approaches to selecting expression
plasmids (especially with respect to their purification tags and pro-
moters), microbial strains and culture conditions to enable the de-
tergent-based purification of functional membrane proteins for bio-
physical characterization and crystallization trials (for subsequent
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Table 1
Unique membrane protein structures derived from recombinant E. coli proteins produced in E. coli (homologous expression).
PDB Name TM1 Length Strain(s) Vector Tag Size N/C2 Solubilization3 Structure4 Date
Monotopic
1B12 Signal peptidase (SPase) 0 280 BL21(DE3) pET3b NT5 IB-gua6 Xray-TX100 1999
1J79, 1XGE Dihydroorotate dehydrogenase 0 347 XL1-Blue NA8 No vector NT5 None None 2001
2QCU Glycerol-3-phosphate dehydrogenase
(GlpD)
0 501 XL1-Blue/JM109 pQE30 His 6 N OG Xray-OG 2008
Alpha-helical
1A91 Subunit C of the F1Fo ATP synthase 2 79 MEG119 NA
8 pC35 NS7 NS7 NS7 NS7 lsNMR-solvent 1998
1FFT Electron transport chain complexes 15+ 2+5+3 663+315+204+109 GO105 NA8 pJRhisB NI9 His 6 C MD10 Xray-OG 2000
1FX8, 1LDF Glycerol facilitator channel (GlpF) 8 281 NS7 NS7 His 6 N OG Xray-OG 2000
1L0V, 5VPN Native fumarate reductase complex
(FrdABCD)
3+ 3 602+244+131+119 DW35 NA8 pH3 NI9 NT5 C12E9 Xray-C12E9 2002
1KQF Formate dehydrogenase-N (FdnGHI) 1+ 4 1015+294+217 GL101 NA8 NF11 NF11 NF11 NF11 2002





3+ 3 115+129+238+588 DW35 NA8 PSDH15 NI9 NT5 C12E9 Xray-C12E9 or
DM or MD10
2003
1OTS, 2EXW, 4FG6 H+/Cl− exchange transporter 14 473 BL21(DE3) pET28b His 6 C DM Xray-DM or
OM
2003
1OY6 Multi-drug efflux transporter (AcrB) 12 1049 DH5α pUC515A NT5 DDM Xray-DDM 2003
1PW4 Glycerol-3-phosphate transporter (GlpT) 12 451 LMG194 pBAD His NS7 C DDM Xray-MD10 2003
1PV7, 2CFQ Lactose permease (LacY) 12 417 XL1-Blue pT7-5 His 10 C DDM Xray-MD10 2003
1Q16, 1SIW, 1Y4Z Nitrate reductase A (NarGHI) 5× 2 1247+512 + 225 LCB2048 pVA700 NT5 C12E9 Xray-C12E9 2003
1RC2, 2O9D, 3NK5 Aquaporin (AqpZ) 8× 4 231 C43(DE3) pET28b His 6 N OG Xray-OG 2003
1U7G Ammonia channel (AmtB) 11× 3 428 C41(DE3) pET29b His 6 C OG Xray-OG 2004
1XQF, 2NMR,
2NUU, 2NS1
Ammonia channel (AmtB) 11× 3 428 C43(DE3) pET22b His 6 C DDM Xray-LDAO 2004
1ZCD Na+ /H+ antiporter (NhaA) 12 388 Rk20+B834DE3 pAXH His NS7 NS7 DDM Xray-MD10 2005
2ABM Aquaporin (AqpZ) 8× 4 231 BL21(DE3) pLysS NS7 His NS7 N OG Xray-OG 2005
1T9T, 2GIF Multi-drug efflux transporter (AcrB) 12 1049 C43(DE3) pUC515A, pET24a
(2GIF)
NT5or His 6 C DDM Xray-DDM or
Cymal6
2005




Multi-drug efflux transporter (AcrB) 12 1053 JM109, W3104
(ΔAcrA/B)
pACBH (pUC118) His 6 C DDM Xray-DDM or
MD10
2006
2J58 Translocon for capsular polysaccharides
(Wza)
1× 8 359 LE392 pWQ126 (pBAD24) NT5 SB3-14 Xray-DDM 2006
2HI7 Periplasmic oxidase complex (DsbB-
DsbA)
4 176+208 M15 pQE70 His 6 C UDM Xray-MD10 2006
2OAU, 2VV5 Voltage-modulated mechanosensitive
channel (MscS)
3× 7 286 BL21(DE3) pET28b His 6 N FC14 Xray-FC14 2007
2HQC Multi-drug efflux transporter (AcrB) 12 1053 BL21(DE3) Gold pSORT1 His 6 C DDM Xray-DDM 2007
2V8N Lactose permease (LacY) 12 417 XL1-Blue pT7-5 His 10 C DDM Xray-MD10 2007




Maltose uptake transporter (MalFGK2) 8 (MalF) + 6
(MalG)
514+296 + 381+370 HN741 pACYC184+PFG23 His 6 C DDM Xray-UDM 2007
3B5D Multi-drug efflux transporter (EmrE) 4× 2 110 BL21(DE3) pET15b His 6 N NG Xray-NG 2007
3DHW Methionine uptake transporter (MetNI) 5× 2 343+217 BL21(DE3) Gold pET19b His 10 N DDM Xray-DDM 2008
3E9J Periplasmic oxidase complex (DsbB-
DsbA)
4 208+176 HM125 pQE70 His 6 C NM Xray-NM 2008
3FI1 Na+ /H+ antiporter (NhaA) 12 388 BL21(DE3) pET His 6 C DDM EM-lipids (2D) 2009
2ZUQ Periplasmic oxidase (DsbB) 4 176 M15 pQE70 His 6 C UDM Xray-DHPC 2009
2WCD Cytolysin A (ClyA, HlyE) 3× 12 309 Tuner(DE3) pET11a His 6 N None Xray-DDM 2009
2KDC Diacylglycerol kinase (DAGK). Domain-
swapped homotrimer
3× 3 122 BL21(DE3) WH1061 pSD005 His 6 N Empigen lsNMR-DPC 2009
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Table 1 (continued)
PDB Name TM1 Length Strain(s) Vector Tag Size N/C2 Solubilization3 Structure4 Date
3JQO Type IV OM secretion complex 1× 14 396 B834(DE3) pASK-IBA3 Strep C MD10 Xray-LDAO 2009
3KCU Aquaporin-like formate transporter
(FocA)
6× 5 285 BL21(DE3) pET21b His 6 C OG Xray-MD10 2009
3LRB, 3L1L, 3OB6 Arginine:agmatine antiporter (AdiC) 12 445 BL21(DE3) pET15b His 6 N DDM Xray-NG 2010
3HFX Carnitine transporter (CaiT) 12 504 C41(DE3) pET28b GFP+His 6 C DDM Xray-MD10 2010
3M9C, 3RKO Electron transport chain complexes I
(NuoLMNAJK)
14+ 14 + 14+3
+ 3+5
613+509 + 485+100 +
147+184
BL21(DE3) NA8 No vector NT5 DDM Xray-MD10 2010
3NMO, 4ENE,
4MQX




2WSX Carnitine transporter (CaiT) 12 504 BL21(DE3) pET15b His 6 N Cymal5 Xray-Cymal5 2010
3O7Q Fucose transporter (FucP) 12 438 BL21(DE3) pET21b His 6 C DDM Xray-NG 2010
3K07, 3NE5 Metal-ion efflux pump (CusA) 12 1055 BL21(DE3) pET15b His 6 N Cymal6 Xray-Cymal6 2010
3QE7 Nucleobase/ascorbate transporter 12 429 Bl21(DE3) pET21b His 6 C DDM Xray-NG 2011
2Y5Y Lactose permease (LacY) 12 417 C43(DE3) pET28 His 6 C DDM Xray-MD10 2011
3TXT, 3UBB Rhomboid protease (GlpG) 6 185 BL21(DE3) pET41b His 8 C DM Xray-NG 2011
3VMA Peptidoglycan glycosyltransferase
penicillin-binding protein 1b
1 768 BL21(DE3) pET15b His 6 N DDM Xray-LDAO 2012
4DJK Glutamate-GABA antiporter (GadC) 12 511 NS7 pET15b His 6 N OG Xray-MD10 2012
4FI3 Vitamin B12 transporter (BtuCDF) 10 326+249 BL21(DE3) CodonPlus pET His 10 N LDAO Xray-C12E8 2012
4GBY Proton:xylose symporter (XylE) 12 491 BL21(DE3) pET15b His 6 N DDM Xray-MD10 2012
4GD3, 3USE O2-tolerant hydrogenase-1 in complex
with cytochrome b
1+1 + 4 372+597 + 235 FT004 NA8 No vector His 6 C TX100 Xray-DDM 2013
2LTQ Periplasmic oxidase (DsbB) 4 176 C43(DE3) pQE70 His 6 C DDM ssNMR-E. coli
lipids
2013
2LZS Twin arginine translocase (TatA) 1× 9 55 BL21(DE3) pLysS pET24a His 6 C C12E9 lsNMR-DPC 2013
4IU9 Nitrate transporter (NarU) 12 462 NS7 pET21b GST NS7 DDM Xray-MD10 2013
4JA3 Proton:xylose symporter (XylE) 12 491 C41(DE3) pTH27 His 6 N DM Xray-DM 2013
4JR9 Nitrate/nitrite exchanger (NarK) 12 463 C41(DE3) pET15b His 8 N DM Xray-DM 2013
3ZE4 Diacylglycerol kinase (DAGK) 3× 3 122 BL21(DE3) pSD005 His 6 N Empigen Xray-DM (LCP) 2013
4AU5 Na+/H+ antiporter (NhaA) 12 388 BL21(DE3) pLysS pET derivative GFP+His 8 C DDM Xray-MD10 2013
3WDO Drug efflux transporter (YajR) 12 454 C43(DE3) pET28a His 6 C DDM Xray-NG 2013
4C48, 5V78 Multi-drug efflux transporter (AcrB/Z) 12+ 1 1049+49 C43(DE3) pET21a/pRSFduet-1 His 6 C DDM Xray-MD10 2014
4PX7 Phosphatidylglycerophosphate
phosphatase B (PgpB)
6 254 C43(DE3) pET28a His 6 C DDM Xray-MD10 2014
4PL0, 5OFR Antimicrobial peptide transporter (McjD) 6× 2 580 C43(DE3) pWaldoGFPd GFP+His 8 C DDM Xray-NG 2014
2MPN Rhodanese (YgaP) 2× 2 68 BL21(DE3) Star pLysS pET3a His 6 N DHPC/LMPG lsNMR-DHPC/
LMPG
2014
4QIQ Proton:xylose symporter (XylE) 12 474 C43(DE3) pET15b His 6 N DM Xray-MD10 2014
4Q65 Peptide transporter (YbgH) 14 493 C43(DE3) pET28a His 8 C DDM Xray-MD10 2014
4QO2 Rhomboid protease (GlpG) 6 200 C43(DE3) pET15b His 6 C DM Xray-NG 2014
4U8V, 5JMN Multi-drug efflux transporter (AcrB) 12 1057 C43(DE3) pET24a His 6 C DDM Xray-DDM 2014
3WVF Insertase (YidC) 5 548 BL21(DE3) pTV118N His 8 C DM Xray-DM (LCP) 2014
4X5M SemiSWEET transporter 3× 2 89 Rosetta™ 2(DE3) pET His 8 C DDM Xray-DDM 2015
4RP9 Vitamin C transporter (UlaA) 10 465 C43(DE3) pET15b or pET21b His 8 C NM Xray-MD10 2015
5AJI Voltage-modulated mechanosensitive
channel (MscS)
3× 7 286 MJF612 pTRcYH6 His 6 C DDM Xray-DDM 2015
4U4V Nitrate/nitrite exchanger (NarK) 12 463 C41(DE3) pET GFP+His 8 C DDM Xray-DDM
(LCP)
2015
4ZYR, 4OAA Lactose permease (LacY) 12 417 C41(DE3) PT7-5 His 6 C DDM Xray-NG 2015
4ZP0 Multidrug resistance transporter (MdfA) 12 410 C43(DE3) pET28a His 6 C DM Xray-MD10 2015
4UXX Diacylglycerol kinase (DAGK) 3× 3 122 WH1061 pTrcHisB His 6 N Empigen Xray-DM (LCP) 2015
5AZC Phosphatidylglycerol: prolipoprotein
diacylglyceryl transferase (Lgt)
7 291 C43(DE3) pET28a His 6 C DM Xray-OG 2016
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Table 1 (continued)
PDB Name TM1 Length Strain(s) Vector Tag Size N/C2 Solubilization3 Structure4 Date
5F5B Rhomboid protease (GlpG) 6 211 C43(DE3) pGEX-6P-1 GST N DDM Xray-CHAPSO
(bicelles)
2016
5KBN F-ion channel homologue (Fluc) 4× 2 126 BL21(DE3) pASK-IBA2 His 6 C DM Xray-DM 2016
5J4N Arginine:agmatine antiporter (AdiC) 12 445 BL21(DE3) pLysS pZUDF21 His 10 C NG Xray-NG 2016
5SV0, 5SV1 (ExbB/ExbD) 3+ 1 244+58 BL21(DE3) pET28b(ExbB) + pCDF-
1b(ExbD)
His 10 C DDM Xray-DDM 2016
5GXB Lactose permease (LacY) 12 417 BL21(DE3) PT7-5 His 6 C DDM Xray-DDM
(LCP)
2016
5T4O F1Fo ATP synthase 5+ 1 + 2 513+460 + 287+177 +
139+271 + 155+79
DK8 NA8 pFV2 NI9 His 6 N Digitonin EM-Digitonin 2016
5IJI Sensor histidine kinase (NarQ) 4 230 SE1 pSCodon1.2 His 6 C DDM Xray-DM (LCP) 2017
5N6H Apoplipoprotein N-acyltransferase (Lnt) 8 512 C43(DE3) pET28a His 6 N LMNG Xray-LMNG
(LCP)
2017
5XHQ Apoplipoprotein N-acyltransferase (Lnt) 8 512 C41(DE3) pET22b His 8 C DM Xray-MD10 2017




1MPF Porin from colicin-resistant (OmpF) 16 340 BZB1107 NA8 Native NT5 OPOE Xray-MD10 1995
1GFM Porin (OmpF) 16 340 Top10 pGEM-7Zf (+) lac NT5 OPOE Xray-MD10 1996
1MPM, 1MAL,
1AF6
Maltoporin (LamB) 18 421 Pop6510 NA8 pAC1 NT5 OPOE XRAY-OPOE or
MD10
1997
1BT9, 3O0E Porin (OmpF) 16 340 BL21(DE3) pGEM-5Zf (+) NT5 SDS Xray-OPOE 1999
1BY3, 1BY5 Ferrichrome-iron receptor (FhuA) 22 747 B834(DE3)/BL21(DE3) pET NT5 OPOE Xray-OPOE 1999
1FEP Siderophore transporter (FecA) 22 747 BL21(DE3) pET17b NT5 TX100 Xray-LDAO 1999
1QJ8 Porin (OmpX) 8 148 BL21(DE3) pLysS pET3b NT5 IB-gua6 Xray-C8E4 1999
1QKC, 1FI1, 2FCP,
1FCP
Ferrichrome-iron receptor (FhuA) 22 747 AW740 [ΔompF
zch:TnlO
ΔotnpCfltuA31] NA8
pHX405 His 6 Oth12 LDAO Xray-DDAO 2000
1EK9, 1TQQ OM protein (TolC) 3× 4 428 BL21(DE3) NA8 pAX629 pACYC184 NT5 TX100 Xray-MD10 2000
1QJP, 1BXW, 1G90 Porin (OmpA) 8 171 BL21(DE3) pET3b, pET14b NT5 IB-gua6 or urea Xray-C8E4,
lsNMR-DPC
2000
1FW2 OM phospholipase A (PldA) 12 275 BL21(DE3) pT7.7 NT5 IB-urea Xray-OG 2001
1HXX Porin (OmpF) 16 340 BL21(DE3)Δomp8 pGEM-5Zf (+) NT5 SDS Xray-OPOE 2001
1I78 OM protease (OmpT) 10 297 BL21(DE3) pET13a NT5 IB-urea Xray-OG 2001
1ILZ OM phospholipase A (PldA) 12 275 BL21(DE3) Δ pldA pND1/pRK3 NT5 IB-urea Xray-OG 2001
1KMO Siderophore transporter (FecA) 22 774 U600 NA8 pSV66 NT5 TX100 Xray-LDAO 2002
1MM4, 1MM5,
1THQ, 3GP6




1ORM, 1Q9F Porin (OmpX) 8 148 BL21(DE3) pLysS pET3b NT5 IB-gua6 lsNMR-DHPC 2003
1NQ (E-H), 2GSK Cobalamin transporter (BtuB) 22 594 BL21(DE3) Star pLysS pET22b NT5 LDAO Xray-MD10 2003
1PNZ Siderophore transporter (FecA) 22 774 BL21(DE3) pET20b His 10 N Elugent Xray-LDAO 2003
1UJW, 2YSU Cobalamin transporter (BtuB) 22 594 TNE012 (tsx−ompA−
ompB−) NA8
pJC3 NT5 OG Xray-LDAO 2003
1T16, 3PGR Long-chain fatty acid transporter (FadL) 14 427 C43(DE3) pBAD His 6 C MD10 Xray-C8E4 2004
2F1V Outer membrane protein (OmpW) 8 197 C43(DE3) pBAD His 6 C LDAO Xray-LDAO or
C8E4
2006
2GRX Ferrichrome-iron receptor (FhuA) 22 747 AW740 NA8 pHX405 His 6 OT11 LDAO Xray-C8E4 2006
2F1C Porin (OmpG) 14 381 C43(DE3) pBAD His 6 C LDAO Xray-OG 2006
2IWW Porin (OmpG) 14 281 C41(DE3) pET26b NT5 IB-urea Xray-LDAO or
OG
2006
2J1N Osmoporin (OmpC) 16 346 BZB1107 NA8 No vector NT OPOE Xray-MD10 2006
2HDI Colicin I receptor (Cir) 22 639 BL21(DE3) pET20b His 6 C Elugent Xray-MD10 2007
2JMM Porin (OmpA) 8 156 BL21(DE3) Gold pET3b NT5 IB-gua6 lsNMR-DHPC 2007
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Table 1 (continued)
PDB Name TM1 Length Strain(s) Vector Tag Size N/C2 Solubilization3 Structure4 Date
2JQY Porin (OmpG) 14 280 BL21(DE3) pLysS pT7-SMC NT5 IB-urea lsNMR-FC12 2007
2QOM Autotransporter (EspP) 12 285 BL21(DE3) PC6H1 His 6 C Elugent Xray-MD10 2007
2VDE OM protein (TolC) 4× 3 460 C43(DE3)/C41(DE3) pET14b His 8 C Tx100 Xray-DDM 2008
2VQI P pilus usher translocation (PapC) 24 515 B834(DE3) pDG2 His 6 C DDM Xray-MD10 2008
3DWN Long-chain fatty acid transporter (FadL) 14 427 C43(DE3) pBAD His 6 C LDAO Xray-C8E4 2008
2WJR (Mb), 2WJQ
(IB)
Porin (NanC) 12 214 BL21(DE3) pLysS pT7 NT5 OPOE, IB-urea Xray-LDAO,
Xray-FC-12
2009
3HW9, 2ZFG Porin (OmpF) 16 340 MH225 NA8 pR272 NT5 OPOE Xray-MD10 2009
2XE1 Osmoporin (OmpC) 16 346 HN705Δomp8 NA8 PHSG575 NT5 SB3-14 Xray-MD10 or
OG
2010
3AEH Hemoglobin protease (Hbp) 12 308 C43(DE3) pET22b His 6 C SB3-12 Xray-OG 2010





3RFZ P pilus (FimD) 24 843+211 + 279 B834(DE3) / pAN2 (fimD) +
pETS1001 (fimC)
Strep+His 6 C DDM Xray-MD10 2011
3OHN P pilus (FimD) 24 558 B834(DE3) pNH297/pETS4 His 6 C DDM Xray-C8E4 2011
4E1S, 1F02 Intimin outer membrane β-domain 12 242 BL21(DE3) pET9/pET21a His 10 N Elugent Xray-LDAO 2012




4J3O P pilus (FimD) 24 843+211 + 154+279 +
144
Tuner(DE3) / pNH237 (fimC) + pAN2
(fimD)
Strep+His 6 C DDM Xray-MD10 2013
2YNK OM lectin (Wzi) 18 456 Top10/B834(DE3) pBAD His 6 C SB3-14 Xray-LDAO 2013
4C00 Autotransporter (TamA) 16 559 BL21(DE3) pET22b His 6 N OG Xray-OG 2013
4K7K Heavy metal efflux pump (CusC) 4× 3 446 BL21(DE3) Star pET15b His 6 C Cymal6 Xray-cymal6 2013
4C4V (BamA) 16 467 (344–810) BL21(DE3) pET30b His 6 C IB-gua6 Xray-LDAO 2014
4UV3 Amyloid secretion channel (CsgG) 4× 9 277 BL21(DE3) pQLinkN Strep C DDM Xray-MD10 2014
4Q79 Amyloid secretion channel (CsgG) 4× 9 277 BL21(DE3) pQLinkN His 6 N LDAO Xray-LDAO 2014
4D5U Porin (OmpF) 16 340 C41(DE3) NA8 No vector NT5 FC12 Xray-FC12 2015
5EKQ β-barrel assembly machine (BamACDE) 16 810+344 + 245+113 BL21(DE3) pJH114 His 8 C DDM Xray-C8E4 2016
5AYW β-barrel assembly machine (BamABCDE) 16 810+392 + 344+245 +
113
C43(DE3) pQLink Strep+His 6 C DDM Xray-MD10 2016
5D0O β-barrel assembly machine (BamABCDE) 16 810+392 + 344+245 +
113
HDB150 pYG120 His 8 C DDM Xray-MD10 2016
5LJO β-barrel assembly machine (BamABCDE) 16 810+392 + 344+245 +
113
BL21(DE3) pJH114 His 8 C DDM EM-DDM 2016
5WQ7 Secretin (GspD) 4× 15 650 DH5a pASK-IBA3c Strep C MD10 EM-MD10 2016
1 Number of transmembrane domains.
2 N- or C-terminal position.
3 Solubilization detergent.
4 Detergent used for structure determination (NB: LCP is lipid cubic phase; lsNMR is solution phase NMR; ssNMR is solid state NMR).
5 No tag.
6 Inclusion bodies solubilized in 6M guanidine hydrochloride.
7 Not specified in PDB or corresponding publication.
8 E. coli membrane protein produced using its native promoter.
9 No induction.
10 Mixed detergent.
11 Not found; article was not accessible.
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structural studies by X-ray crystallography, as well as the newly-in-
vigorated technique of electron microscopy [7]). We have experience of
automated methods using robots that, once commissioned and opti-
mized, can dramatically increase the number of constructs and hosts
explored and reduce the time required to reach success. This review is
intended for laboratories without access to such facilities, meaning that
the approaches discussed here should be widely applicable.
2. An overview of microbial expression hosts, tags and promoters
2.1. An overview of microbial host usage
The expression systems used in generating high-resolution struc-
tures of recombinant membrane proteins have been documented by
Stephen White in his analysis of the PDB (blanco.biomol.uci.edu/
mpstruc/). Biophysical studies of membrane proteins (especially NMR
and crystallographic techniques) require large quantities (0.1–10mM)
of homogenous, correctly-folded, purified protein; a focus on data ex-
tracted from the PDB has therefore allowed us to identify systems that
have the capability of producing the required quantity and quality of
these challenging targets. This review updates our previous study [8] of
E. coli expression systems and extends that work to include S. cerevisiae
and P. pastoris. Together, these three host systems account for the
production of the vast majority of recombinant membrane proteins in
microbes, although Lactococcus lactis (see PDB entry 4US3), Pseudo-
monas fluorescens (5KUD) and Schizosaccharomyces pombe (2PNO) have
also been used successfully as microbial cell factories in a minority of
cases.
In November 2017, of the 729 unique membrane protein structures
(uMPS) derived from recombinant proteins and deposited in the PDB,
521 were produced in microbial host cells. E. coli was clearly the cell
factory of choice (producing 468 uMPS, Tables 1 and 2), followed by
the yeast hosts, P. pastoris (31 uMPS, Table 3) and S. cerevisiae (22
uMPS, Table 4). Table 5 summarizes the use of microbial expression
systems and the origin of the target uMPS. With a growing number of
uMPS being deposited in the PDB, heterologous membrane protein
production is becoming dominant over the production of homologous
targets. Higher eukaryotic uMPS, in particular, have more recently been
obtained using all three microbial systems (Table 5).
Yeast expression systems have been used almost exclusively in the
production of large, eukaryotic membrane proteins; in the case of P.
pastoris, the targets were mainly of mammalian and plant origin
(Table 3). Yeast hosts have mainly produced α-helical membrane pro-
teins, while E. coli has also been used to produce β-barrel proteins,
probably because many such proteins are found natively in the E. coli
outer membrane (Fig. 1).
Fig. 2 shows that above 500–600 amino acids (∼50–60 kDa), the
number of uMPS decreases dramatically, suggesting that E. coli cannot
efficiently produce large proteins; this may be because ribosomes drop
off very long mRNAs leading to incomplete synthesis products. In
contrast, yeast expression systems can cope with larger proteins up to
1400 residues in length (∼150 kDa) (Fig. 2). When we interrogated the
data for eukaryotic (mammalian, plant, fish, anemone and worm)
membrane proteins produced in E. coli (Table 6), we identified 47
uMPS. Of these 47 uMPS, 7 were monotopic membrane proteins and 23
were small peptides or proteins containing only one transmembrane
domain. Fifteen uMPS were produced as inclusion bodies and subse-
quently refolded, 17 were purified in mild detergent and, of those, 3
were membrane proteins with more than 4 transmembrane α-helices
that had been crystallized in the presence of detergent (PDB codes:
2Q7M; 4BUO; 4O6Y) and 1 was studied by electron microscopy
(3DWW).
2.2. An overview of tag usage in microbial expression systems
Construct design is an integral part of defining an appropriate
expression system, with key considerations being the size and predicted
secondary structure of the target protein as well as the planned pur-
ification strategy. SMART (protein domain identification; http://smart.
embl-heidelberg.de/help/smart_about.shtml) or Jpred (secondary
structure prediction; http://www.compbio.dundee.ac.uk/jpred/) ap-
proaches can be used to describe the protein architecture and may help
in deciding where to place any tags.
Addition of a polyhistidine tag is the most popular strategy for large-
scale purification of recombinant membrane proteins on nickel-affinity
columns. This is especially true for E. coli, where other affinity pur-
ification tags have had very little impact: 392 of the 447 tagged proteins
produced in E. coli contain a polyhistidine tag; 18 contain a GFP tag and
17 were fused to maltose binding protein (MBP). Other tags such as
Strep and Flag account for no more than 13 uMPS (Fig. 3A, Tables 1 and
2). While the overall numbers are lower for uMPS from yeast-derived
proteins, GFP is emerging as a useful tag to track the purification of
proteins from yeast membranes (Fig. 3B, Tables 3 and 4). GFP can be
particularly useful for monitoring production yields or the oligomeric
state of a membrane protein-GFP fusion via fluorescent size exclusion
chromatography experiments (F-Sec) [9]. Other tags (e.g. Strep and
Flag) are also more frequently used in yeast expression systems
(Fig. 3B).
Irrespective of the host used, polyhistidine tag placement is ap-
proximately equally favoured at the amino- or carboxyl-terminus of the
target protein (Fig. 4A, Tables 1–4). For constructs with amino-terminal
tags, protein synthesis is usually initiated using a sequence of at least
three amino acids before that of the tag. For example, in plasmid pRSET
(Invitrogen), the sequence is MRGSHis6, while the protein used to solve
structure 4V3G contained the following amino-terminal tag: AN-
VRLQHis7LE (Table 2). Fig. 4B shows that 35% of uMPS produced in
microbial host cells contained polyhistidine tags with more than 6
histidines. An interesting example is the insertion of a tandem array of 6
histidines separated by a glycine (see 5DO7, Table 3).
Fluorescent tags are an increasingly popular choice for examination
of protein quality [10]. In bacteria, dual Ribosome-Binding-Site (RBS)
expression vectors such as pET-Duet (Novagen) enable the cloning of a
gene encoding a reporter fluorescent protein downstream of the target
gene. This allows the cell population to be assessed by flow cytometry
for stability and toxicity of the expression construct and to establish
optimal induction conditions. Double RBS vectors from the pET-Duet
series have been used to produce nine multi-subunit membrane proteins
(see Table 2 for 4HZU, 4HUQ, 4HG6, 4NRE, 4N4R, 5AWW, 4YMS,
3DL8 and Table 1 for 4C48), with five being produced in E. coli host
strain C43(DE3).
There is no general rule regarding cleavage sequences, but TEV
protease, which is easy to produce in-house, is widely used for mem-
brane protein purification (see 4C00, 3WVF, 4X5M and 4JA3 for ex-
amples) because it is still active in the presence of the most commonly-
used detergents [11]. Thrombin protease is also widely used (see 2VQI,
2ABM and 3B5D for examples).
2.3. Promoter usage for E. coli expression
We analyzed how the 468 membrane proteins in Table 5 had been
produced. Some uMPS were produced in more than one expression
system and therefore Tables 7 and 8 list a total of 477 combinations of
promoter and E. coli host strain. As we previously observed (in our 2015
analysis of 213 uMPS [8]), the T7 RNA polymerase (T7RNAP)-based
expression system is the most widely-used followed by the ara, T5 and
tet promoter-based expression systems (Fig. 5). The data in Tables 1 and
2 are presented in chronological order, meaning that the later entries
reflect the most recent trends in promoter, strain and vector choice.
For the production of non-E. coli (heterologous) membrane proteins
in an E. coli host, the T7RNAP-based expression system is pre-
dominantly used together with six bacterial strains, BL21(DE3),
C43(DE3), C41(DE3), BL21(DE3) pLysS, BL21(DE3) CodonPlus or
M.V. Dilworth et al. Methods xxx (xxxx) xxx–xxx
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Table 2
Unique membrane protein structures derived from recombinant non-E. coli proteins produced in E. coli (heterologous expression).
PDB Organism Name TM1 Length Strain(s) Vector Tag Size N/C2 Solubilization3 Structure4 Date
Monotopic
1UUM R. rattus Flavin dihydroorotate
dehydrogenase (DHOD)
0 372 XL1-Blue pASKDr His 6 N None Xray-OG 2004
2FNQ, 3FG4 P. homomalla Lipoxygenases (LOXs) 0 699 BL21(DE3) NS5 His 6 N None None 2006
2OQO A. aeolicus Peptidoglycan
glycosyltransferase (PGT)
0 200 BL21(DE3) pET48b His 6 N CHAPS CHAPS 2007
2PRM H. sapiens Dihydroorotate dehydrogenase
(DHODH)
0 367 BL21(DE3) pET19b His 10 N TX100 Xray-MD6 2008




3I65 P. falciparum Dihydroorotate dehydrogenase
(PfDHODH)
0 415 BL21(DE3) pET28b His 6 N C12E9 Xray-LDAO 2009
3L7I S. epidermidis Polymerase (TagF) 0 729 BL21(DE3) pET28b His 6 C CHAPS Xray-CHAPS 2010
3O8Y H. sapiens Enzyme 5-lipoxygenase (5LOX) 0 691 Rosetta™ 2(DE3) pET14b His 6 N None None 2011
2XCI A. aeolicus Glycosyltransferase (WaaA,
KdsB)
0 374 BL21(DE3) CodonPlus pUM212/216 His 10 N TX100 Xray-Cymal6 2011
3RST, 4KWB B. subtilis Signal peptide peptidase A
(SppA)
0 240 BL21(DE3) Tuner pET28b His 6 N None Xray-DDM 2012
4EHW A. aeolicus Kinase (LpxK) 0 317 C41(DE3) pET21b GST N DDM Xray-DDM 2012
4G9K S. cerevisiae NADH dehydrogenase (Ndi1) 0 471 BL21(DE3) pLysS pET16b His 10 N DDM Xray-DDM or
DM
2012
4GGM C. crescentus Phosphodiester hydrolase (LpxI) 0 283 C41(DE3) T7 based His 10 N None None 2012
4G6G S. cerevisiae Dehydrogenase (Ndi1) 0 502 C43(DE3) pQE80L His 6 N TX100 Xray-TX100 2012
4HHS A. thaliana Fatty acid α-dioxygenase (α-
DOX)
0 652 M15 pQE30 His 6 N DM Xray-NG 2013
3VV9 T. brucei Alternative oxidase (AOX) 0 329 BL21(DE3) pET15b His 6 N OG Xray-MD6 2013
2YOC K. oxytoca Lipoprotein pullulanase (PulA) 0 1078 pAP5198 pCHAP4486 His 6 C NS5 NS5 2013
4NRE H. sapiens Enzyme 15-lipoxygenase-2
(15LOX-2)
0 696 Rosetta™ 2(DE3) pETDuet-1 His 6 N None None 2014
4NM9 G. sulfurreducens Proline utilization A (PutA) 0 1005 BL21AI pNIC28-Bsa4 His 6 N None None 2014
4NWZ C. thermarum Non-proton pumping type II
NADH dehydrogenase (NDH-2)
0 405 C41(DE3) pTRCndh2 His 6 C OG Xray-OG 2014
4PLA H. sapiens Phatidylinositol 4-kinase type IIa
(PI4K IIa)
0 556 BL21(DE3) Star pRSFD His 6 N None None 2014
4QN9 H. sapiens Fatty-acid ethanolamides (FAEs) 0 393 Rosetta-origamiB (DE3)
pLysS
pMAL MBP+His 6 C TX100 Xray-DC 2015
4WVG S. aureus Bacterial type I signal peptidases 0 542 BL21(DE3) CodonPlus pProExHta MBP N None None 2015
5B49 P. aeruginosa UDP-diacylglucosamine
pyrophosphohydrase (LpxH)
0 248 B834(DE3) pLysS pET26b His 6 C TX100 None 2016















2CPB Phage M13 Major coat protein of M13 1 50 K38 NF7 NF7 NF7 lsNMR-FC12
or SDS
1998
1F6G S. lividans Potassium channel (KcsA) 2×4 160 XL1-Blue pQE32 His 4 N or C DDM 2001
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Table 2 (continued)












Potassium channel (MthK) 2× 4 340 XL1-Blue, SG1309 pQE70 His 6 C DM Xray-LDAO 2002
1ORQ, 2A0L,
2KYH
A. pernix Channel (KyAP) 6 223 XL1-Blue pQE60 His 6 C DM Xray-DM 2003
1XFH, 3KBC,
3V8F
P. horikoshii Glutamate transporter homol
(GltPh)
8× 3 422 TOP10 or DH10B pBAD His 8 N DM Xray-DM 2004








2B2F A. fulgidus Transporter (Amt-1) 11×3 399 C43(DE3) pET21a His 6 C DDM Xray-LDAO 2005
2F2B M. marburgensis Aquaporin (AqpM) 6×4 246 BL21(DE3) CodonPlus NS5 His 10 N OG Xray-OG 2005
2BBJ T. maritima Mg2+ transporter (CorA) 2× 5 351 NS5 pET15b His 6 N DDM Xray-DDM 2005







B. cereus Channel (NaK) 2× 4 '96–114 SG1309 pQE60 His 6 C DM Xray-DM 2006
2HN2, 2IUB T. maritima Transporter (CorA Mg2+) 2× 5 351 BL21(DE3) CodonPlus pET15b His 6 N DDM Xray-DDM 2006
2H3O M. morganii Transporter (MerF HgII) 2 61 BL21(DE3) pLysS pET31 His 6 C IB-gua ssNMR-14-O-
PC/6-O-PC
2006
2HAC H. sapiens TCR-CD3, TM dimer complex 1× 2 33 BL21(DE3) pMM-LR6 His 9 N IB-gua+TX100 lsNMR-SDS/
FC12
2006
2NR9 H. influenzae Intramembrane peptidase (GlpG) 6× 2 196 TOP10 pBAD His 6 C DDM Xray-C12E8 2006
2NWL P. horikoshii Aspartate transporter (GltPh) 8 422 Top10 pBAD24 His 8 NS5 DDM Xray-DM 2007
2JO1 H. sapiens Phospholemman (FXYD1) 1 72 C43(DE3) pETBcl-XL Bcl-XL+His 6 N IB-gua lsNMR-SDS 2007
2Q7M H. sapiens Lipoxygenase protein (FLAP) 4× 3 161 BL21(DE3) pET28a His 6 C DDM Xray-MD6 2007
2QJU A. aeolicus Leucine transporter (LeuT) 12 511 BL21(DE3) pLysS pBAD His NS5 NS5 DDM Xray-OG 2007
2YVX, 2ZY9 T. thermophilus Transporter (MgtE) 5× 2 473 C41(DE3) pET28a His 6 N DDM Xray-DDM 2007
3B9W N. europaea Rh protein ammonia or CO2
channel
11 407 GT1000 D (glnK, amtB) pAD7; nitrogen
promoter
His 6 C OG Xray-OG 2007
3B60 S. typhimurium Flippase (MsbA) 6× 2 582 BL21(DE3) pET19b His 10 N UDM Xray-UDM 2007
3BEH M. loti Cyclic nucleotide-regulated K+
channel
6× 4 355 JM83 pASK-IBA2 His 6 C DM Xray-DM 2008
2LJB, 2RLF Influenza A, B Channel (M2) 1× 4 35 BL21(DE3) pMM-LR6 His-trpLE 9 N IB-gua+TX100 lsNMR-
DHPC
2008
2VL0 E. chrysanthemi Channel (pentameric ELIC) 4× 5 321 BL21(DE3) pET26b MBP+His 10 N UDM Xray-UDM 2008
2VQG C. glutamicum Porin B (PorB) 1× 5 99 BL21(DE3) pGEX-3X GST N None Xray-C10E9,
OG, NG, DM
2008
3DH4 V. parahaemolyticus Na+/galactose transporter
(ySGLT)
14 530 XL1-Blue pBAD His 6 C DM Xray-DM 2008
2K1L H. sapiens Receptor tyrosine kinase
(EphA1)
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Table 2 (continued)
PDB Organism Name TM1 Length Strain(s) Vector Tag Size N/C2 Solubilization3 Structure4 Date







BL21(DE3) pBAD22, pACYC No tag DDM Xray-Cymal6 2008
2ZJS T. thermophilus Translocon (SecYE) 10+1 438+60 AD202 pTV118N lac His 6 C DDM Xray-DDM 2008
2JLN, 2X79 M. liquefaciens Benzyl-hydantoin transporter
(Mhp1)
12 501 BLR pTTQ18 His 6 C DDM Xray-NM 2008





C43(DE3) pET Duet-1, pCDF
Duet-1









A. aeolicus VF5 Symporter (LeuT) 12×2 519 C41(DE3) pET16b His 8 C DDM Xray-OG 2008
2V50 P. aeruginosa Transporter (MexB) 12×3 1052 C43(DE3) pET28 His 6 C DDM Xray-DDM 2009
4DOJ, 2WIT C. glutamicum Glycine betaine transporter
(BetP)
12×3 566 DH5a, BL21(DE3)
CodonPlus
IBA7 Strep N DDM Xray-Cymal5 2009
3DWW H. sapiens Prostaglandin E synthase 1 4× 3 158 BL21(DE3) pLysS pSP19T7LT His 6 N TX100 EM-TX100 2009
2K9Y H. sapiens Receptor tyrosine kinase (Eph2) 1 41 BL21(DE3) pLysS pGEMEX1 TrxA-His NS5 N TX100 NMR-MeOH/
CHCl3/water
2009
3GIA M. jannaschii Protein MJ0609 (ApcT) 12 444 C41(DE3) pET3a-GFP GFP+His 8 C DDM Xray-OTG 2009
2KNC H. sapiens Integrin αIIbβ3 1+1 54 and 79 BL21(DE3) pMAL-C2 MBP-His 6 N TX100 lsNMR-
CD3CN/H2O
2009
3K3F D. vulgaris Transporter (urea) 10×3 533 BL21(DE3) pET-SUMO SUMO+His NS5 N DDM Xray-OM 2009
3IGA S. lividans Potassium channel (KcsA) 2× 4 124 JM83 pASK90 His 6 N DM Xray-DM 2009
2KOG R. norvegicus Synaptobrevin 1 119 BL21 (DE3)/BL21(DE3)
pRil
pET15b/28a His 6 N Sodium cholate lsNMR-FC12 2009
3KLY V. cholerae Formate transporter (FocA) 6× 5 280 C43(DE3) pBAD His 10 C DDM Xray-OG 2009
3KP9 Synechococcus sp. Thioredoxin domain protein
(VKORC1)
5 291 C43(DE3) pET20b His 6 C DDM Xray-DDM 2010
4NV5, 3KP9 Synechococcus sp. Vitamin K epoxide reductase
(VKOR)
5 291 BL21 (DE3) NS5 His 6 C DDM Xray-DDM 2010
3M71 H. influenzae Anion channel (SLAC1) 10×3 328 BL21(DE3) pLysS pET His 10 C DDM Xray-LDAO
or OG
2010




3NCY S. enterica Antiporter (AdiC) 12×2 445 BL21(DE3) pASK-IBA2 His 6 N DM Xray-DM 2010




3MKT V. cholerae MATE transporter (NorM) 12 461 BL21(DE3) pET19b His 10 N DDM Xray-DDM 2010
3MP7 P. furiosus Primed channel (SecYEb) 10 (Y)
+ 1 (E)
482+61 BL21AI pBAD His 6 C DDM+OG Xray-OG 2010
3P5N S. aureus Transporter (RibU) 6× 2 189 BL21(DE3) pET15b His 6 N NG Xray-NG 2010
2L35 H. sapiens Signaling module (DAP12) 2+ 1 63+32 BL21(DE3) pMM-LR6 His-trpLE 9 N IB-Gua+TX100 lsNMR-
FC14+SDS
2010











G. violaceus Channel (pentameric GLIC) 4× 5 317 BL21(DE3) pET26b MBP+His 10 N DDM Xray-DDM 2010
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Table 2 (continued)
PDB Organism Name TM1 Length Strain(s) Vector Tag Size N/C2 Solubilization3 Structure4 Date
2XQA, 3EHZ,
4HFI
2XQ2 V. parahaemolyticus Na+/galactose transporter
(ySGLT)
14 593 TOP10 pBAD His 6 C DM Xray-Tri-DM 2010
2XUT S. oneidensis Transporter (PepTSt) 14 524 C43(DE3) pWaldo-GFPe GFP+His 8 C DDM Xray-DDM 2010







G. violaceus Ligand-gated ion channel (GLIC) 4× 5 359 C43(DE3) pET20b MBP+His 6 N DDM Xray-DDM 2011
3PJZ V. para-hemolyticus Transporter (TrkH) 10×2 485 BL21(DE3) pET31 His 10 C DM Xray-DM 2011
3ND0 Synechocystis sp. pcc
6803
H+/Cl− exchange transporter 18 466 420399 pASK His 6 C DM Xray-DM 2011
3ODJ H. influenzae Peptidase (GlpG) 6 196 TOP10 pBAD His 6 C DDM Xray-C12E8 2011
3QNQ B. cereus Transporter (ChbC EIIC) 10×2 433 BL21(DE3) pET His 10 C DDM Xray-NM 2011




3AQP T. thermophilus (SecDF) 12 735 BL21(DE3) CodonPlus pET26b His 6 C DDM Xray-DDM 2011
2L9U H. sapiens Transmembrane domain (ErbB3) 1× 2 40 Cell-free expression pET22b His 6 C Cell-free
expression-pellet
lsNMR-FC12 2011
3RFU L. pneumophila Copper efflux ATPase 8 736 C43(DE3) pET22b His 6 C C12E8 Xray-MD6 2011
3RCE Campylobacter lari OST in complex (PglB) 13 724 BL21-Gold SCM6 pBAD His 10 C DDM Xray-DDM 2011
4BBJ, 3RFU L. pneumophila Copper-transporting ATPase
(LpCopA)
8 736 C43(DE3) pET22b His NS5 NS5 C12E8 Xray-C12E8 2011
3S0X M. maripaludis Preflagellin aspartyl protease
(FlaK)
6 237 C43(DE3) pET28a/43b His 6 C FC12 Xray-Cymal6 2011
2LCK M. musculus Mitochondrial uncoupling
protein 2 (UCP2)




N. pharaonis Rhodopsin (SRII) 7 239 BL21(DE3) and
BL21(DE3) Tuner





3ZUY N. meningitidis Bacterial ASBT homologues 10 323 C43(DE3) pWaldo-GFPe GFP+His 8 C DDM Xray-LDAO 2011
3ZRS, 2WLJ,
4LP8
M. magneto-tacticum Channel (KirBac3.1) 2× 4 339 BL21(DE3) CodonPlus pET30a His 6 C DM Xray-
HEGA10
2012
4A2N M. acetivorans Transferase (ICMT) 5 194 C41(DE3) pTriEX/pOPIN GFP+His 7 C DDM Xray-DDM 2012
3AYF G. stearo-
thermophilus
Nitric oxide reductase (qNOR) 14 800 Rosetta2 (DE3)
BL21(DE3) CodonPlus
pET22b His 6 C TX100 Xray-OG 2012
3V5U M. janaschii Exchanger (Na+/Ca+) 9 320 BL21(DE3) pLysS pQE60 His 10 C DDM Xray-DDM
(LCP)
2012
3TIJ V. cholerae Nupc family protein 8× 3 424 C41(DE3) pET26 MBP+His 10 N DDM Xray-DM 2012
3RQW E. chrysanthemi Ligand-gated ion channel with
acetylcholine (ELIC)
4× 5 322 Rosetta™ 2(DE3) pLysS pET26b His 10 N UDM Xray-DDM 2012
3TDO C. difficile Hydrosulfide ion channel (FNT3) 6× 5 268 BL21(DE3) pLysS pBAD His 10 C DDM Xray-OG 2012
3QF4 T. maritima Heterodimeric ABC exporter 6× 2 587 C43(DE3) or MC1061 pBAD24 His 10 N DDM X-ray-DDM 2012





NaK chimera with NaV 2×4 148 KRX pET21b His 4× 6 Oth8 DM Xray-DM 2012
2LCX H. sapiens ErbB4 1×2 44 BL21(DE3) pLysS pGEMEX1 TrxA-His 6 N TX100 2012
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Table 2 (continued)






Na+ channel (NaV) 6× 4 228 BL21(DE3) pET21b His 6 C DDM Xray-NG 2012
4APS S. thermophilus Transporter (PepTSo) 12+2 491 C43(DE3) pWaldo-GFPe GFP+His 8 C DDM Xray-DDM 2012
4F8H G. violaceus Ligand-gated ion channel with
ketamine (GLIC)
4× 5 359 Rosetta™ 2(DE3) pLysS pET26b MBP+His 10 N DDM Xray-TDM 2012
4F4L M. marinus Voltage-gated sodium channel
pore
2× 4 112 C41(DE3) pET15b His 6 N DDM Xray-MD6 2012
2LNL H. sapiens Receptor (CXCR1) 7 309 BL21(DE3) pGEX2a GST+His 6 C IB-SDS ssNMR-
DMPC
2012
4F35 V. cholerae Symporter 11×2 462 BL21(DE3) pET His 10 N DM Xray-MD6 2012
4EV6 M. jannaschii Transporter (CorA Mg2+) 2× 5 317 Rosetta™ 2(DE3) pNIC28 (pET28) His 6 N UDM Xray-UDM 2012
4H33 L. monocytogenes Channel (KyLm) 2× 4 137 XL1-Blue pQE70 His 6 C DM Xray-DM
(LCP)
2012
4EEB T. maritima Mg2+transporter (CorA) 2× 5 351 BL21(DE3) CodonPlus pET15b His 6 N DDM Xray-DDM 2012
4B4A A. aeolicus Twin-arginine translocase (TatC) 6 240 Lemo56(DE3) pWaldo-GFPe GFP+His 8 C LMNG Xray-LMNG 2012
3UX4 H. pylori Channel (urea) 6× 6 195 C43(DE3) pET His 6 Oth8 DM Xray-MD6 2012
4HYG M. marisnigri Presenilin (PSH) 9× 4 301 BL21(DE3) pET21b His 8 N NM Xray-MD6 2012
4HG6 R. sphaeroides Cellulose synthase (BcsA-BcsB) 8+ 1 802+707 Rosetta™ 2(DE3) pETDuet His 12 N TX100 Xray-LDAO 2012
4G1U Y. pestis Transporter (HmuUV) 10×2 334 BL21(DE3) Gold pET19b His 10 N DDM Xray-DDM 2012
4GX0 G. sulfurreducens Channel (GsuK) 2× 4 565 BL21(DE3) pQE70 His NS5 C DM Xray-DM 2012
2LOU H. sapiens Apelin receptor 1 64 BL21(DE3) pEXP5-CT His 6 C IB- acetonitrile
/trifluoroacetic acid
lsNMR-FC12 2013
3ZKR E. chrysanthemi Ligand-gated ion channel (ELIC) 4× 5 307 C43(DE3) pET11a MBP N UDM Xray-UDM 2013
4HUK N. gonorrhoeae MATE transporter (NorM) 12 459 BL21(DE3) pET15b His 6 N DDM Xray-DDM 2013
3VVN P. furiosus Multidrug and toxin compound
extrusion (MATE)
12 461 C41(DE3) ΔacrB pET11a His 6 C DDM Xray-Cymal6
(LCP)
2013
4J9U V. parahaemolyticus Potassium ion transporter (TrkH) 10×2 485 BL21(DE3) pET31b His NS5 C DM Xray-DM 2013
4HZU L. brevis ECF transporter complex 2+ 5 166+266 C43(DE3) pRSF-Duet-1 His 12 N DDM Xray-DM 2013
4HUQ L. brevis Folate ECF transporter
(FolT+ EcfT)
2+ 5 174/280 BL21(DE3) PET-Duet His 6 N DDM Xray-DM 2013
4J7C B. subtilis Potassium ion transporter
(KtrAB)
8× 2 465+222 BL21(DE3) pET24d His NS5 N DDM Xray-Cymal6 2013
4HTS A. aeolicus Twin-arginine translocase (TatC) 6 236 BL21(DE3) pET33b His 6 N DDM Xray-DHPC
or DDM
2013









Proteorhodopsins (PRs), 7 259 C43(DE3) pET28a His 6 C DM Xray-DM 2013
2M6X Hepatitis C virus p7 hexamer channels 2× 6 63 BL21(DE3) pMM- LR6 His-trpLE 9 N IB-gua+TX100 lsNMR-FC12 2013
4KPP A. fulgidus Ca2+/H+ antiporter (CaX) 12 405 C41(DE3) pET GFP+His 8 C DDM Xray-DMNG
(LCP)
2013
4KJS B. subtilis Ca2+/H+ antiporter (YfkE) 11×3 351 BL21(DE3) pET22b His 6 Oth8 DDM Xray-DDM 2013
3W9J P. aeruginosa Multi-drug efflux transporter
(MexB)
12×3 1052 MG1655 pUCP20-BHis His 10 C DDM Xray-DDM 2013
4IKV G. kaustophilus Proton-dependent oligopeptide
transporter (POT)
12 507 C41(DE3) ΔacrB pCGFP-BC GFP+His 8 C DDM Xray-DDM
(LCP)
2013









4BWZ T. thermophilus Na+/H+ antiporter (NapA) 12×2 394 Lemo21(DE3) pWaldo-GFPe GFP+His 8 C DDM Xray-NM 2013
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Table 2 (continued)
PDB Organism Name TM1 Length Strain(s) Vector Tag Size N/C2 Solubilization3 Structure4 Date
2M6B H. sapiens Glycine receptor (hGlyR-α1) 4× 5 150 BL21(DE3) pLysS pET31b His 6 C IB-NS5 lsNMR-LPPG 2013
4J72, 5CKR A. aeolicus MurNAc-pentapeptide
translocase (MraY)
10 365 C41(DE3) NS5 MBP+His 10 N DDM Xray-DM 2013
4KY0 T. kodakarensis Aspartate transporter 8 431 MC1061 pBAD24 His 8 C DM Xray-OG 2013
3ZJZ, 4CBC,
5BZB
M. marinus Sodium channels 4 149 C41(DE3) pET15b His NS5 NS5 DDM Xray-
HEGA10
2013
2LZL H. sapiens Growth factor receptor 3
(FGFR3)
1× 2 43 BL21(DE3) pLysS pGEMEX1 TrxA-His 6 N TX100 lsNMR-
FC12/SDS
2013
4M8J P. mirabilis Carnitine transporter (CaiT) 12×3 504 BL21(DE3) pLysS pET15b FLAG-His 6 C Cymal5 Xray-Cymal5 2013
4LDS S. epidermidis Glucose/H+ symporter (GlcP) 12 446 C41(DE3) pET15b His NS5 N DDM Xray-DDM 2013
4K0J C. metallidurans ZneA Zn(II)/proton antiporter 12 1045 C43(DE3) pET30b His 6 C DDM Xray-DDM 2013
4LTO A. ehrlichii Voltage-gated sodium channel
(NaVAe1p)
2× 4 152 C41(DE3) pET24 MBP+His 6 N DDM Xray-DDM 2013
4LZ6, 5C6N B. halodurans MATE transporter (DinF-BH) 12 446 BL21(DE3)
ΔacrABΔmacABΔyojHI
pET15b His 6 C DDM Xray-DDM 2013
3WAJ A. fulgidus OST (AglB) 13 875 C43(DE3) pET52b His 10 C DDM Xray-MD6 2013
4C7R C. glutamicum Glycine betaine transporter
(BetP)
12×3 566 DH5α pIBA7 Strep N DDM Xray-Cymal5 2013
2MAW H. sapiens Neuronal acetylcholine receptor 4 137 Rosetta™ 2(DE3) pLysS pMCSG7 His 6 N NS5 lsNMR-LDAO 2013
2M8R, 3HD7 R. norvegicus Syntaxin 1A, TM & syntaxin
complex




4CAD M. maripaludis Protease Rce1 (CAAX) 8 271 C41(DE3) pTriEX His 7 C UDM Xray-MD6 2013
4N7W Y. frederiksenii Bile acid symporter 10 307 BL21(DE3) Gold pET His 10 N DDM DM 2013
4M64 S. typhimurium Na+/melibiose symporter (MelB) 12 476 DW2 pK95 native His 10 C UDM Xray-MD6 2014
4BUO R. norvegicus Neurotensin receptor (NTS1) 7 335 BL21 Tuner pBR322 MBP+His 6 N MD6 Xray-MD6 2014
4O6Y A. thaliana Cytochrome B561 (Cyt b561-B) 6 230 BL21(DE3) pET15b His 6 NS
5 DM Xray-NG 2014
4O9Y P. luminescens Tc toxin (TcA) 2× 5 2516 BL21(DE3) CodonPlus pET28a His 6 N None None 2014
2M59 H. sapiens Endothelial growth factor
receptor 2






4MRN N. aromaticivorans ABC transporter (NaAtm1) 6× 2 614 BL21(DE3) pJL-H6/pET21a His 6 C MD6 Xray-MD6 2014
4MYC S. cerevisiae ABC transporter (Atm1) 6× 2 598 NS5 pASK-IBA1 Strep C DDM Xray-DDM 2014
2MFR H. sapiens Insulin receptor (AAs 940–980) 1 57 BL21(DE3) pET29b His 6 C IB-urea lsNMR-FC12 2014
2MGY M. musculus Translocator protein (TSPO) 5 169 BL21(DE3) pET15b His 6 N IB-SDS lsNMR-FC12 2014
3WO6 B. halodurans Insertase (YidC) 5 267 C41(DE3) pET His or
GFP+His
8 N/C DDM Xray-DDM
(LCP)
2014
4O6M A. fulgidus Alcohol phosphotransferase
(AF2299)
6 372 BL21(DE3) pLysS pMCSG7 His 10 N DM Xray-DM
(LCP)
2014
4PGR B. subtilis pH-sensitive channel (YetJ) 7 214 BL21(DE3) pLysS pET or pMCSG His 10 N DDM Xray-LDAO
or C10E5
2014
4X2S, 4P19 P. horikoshii Aspartate transporter (GltPh) 8 422 DH10B pBAD24 His 8 C DDM Xray-DM 2014
4MND A. fulgidus CDP-alcohol
phosphatidyltransferase
6 479 C43(DE3) pET52b His 10 C TX100 Xray-TX100
(LCP)
2014
4TPH S. oneidensis Oligopeptide-proton symporter
(PepTSo)
14 516 C41(DE3) pNIC-CTHF(pET) His 6 C DDM Xray-DDM 2014
4Q4H T. maritima ABC exporter 6+ 6 587+598 C43(DE3)
MC1061
pBAD24 His 10 N DDM Xray-DDM 2014
4TQ3 A. fulgidus UbiA homolog 9 303 BL21(DE3) pET His NS5 N DM Xray-OG
(LCP)
2014
4MT1 N. gonorrhoeae Multidrug efflux pump (MtrD) 12 1056 C43(DE3) ΔacrB pET15bΩmtrD His 6 C Cymal6 Xray-Cymal6 2014
4QNC, 5UHQ L. biflexa SemiSWEET 3 85 BL21(DE3) pJexpress411 His 10 C DDM Xray-DDM 2014
4QND Vibrio sp. n418 3×2 97 BL21(DE3) pJexpress411 His 10 C DDM Xray-DDM 2014
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Table 2 (continued)
PDB Organism Name TM1 Length Strain(s) Vector Tag Size N/C2 Solubilization3 Structure4 Date
SemiSWEET in outward-open
state
4TWD D. chrysanthemi Ligand-gated ion channel with
Br-memantine (ELIC)
4× 5 307 C43(DE3) pET11a MBP N UDM Xray-UDM 2014
4WD7 K. pneumoniae Bestrophin homolog (KpBest) 4× 5 301 BL21(DE3) pLysS pMCSG7 His 10 N DDM Xray-DDM 2014
4QTN N. mucosa Vitamin B3 transporter (PnuC) 8× 3 863 MC1061/BL21(DE3) pBAD/pET21d
(SeMet)
His 6 C DDM Xray-OG 2014
4QUV M. alcaliphilum Δ14-sterol reductase (MaSR1) 10 427 C43(DE3) pET21b His 8 N DDM Xray-NG 2014
4WGV S. capitis Transition-metal ion transporter
(NRAMP)
11 415 MC1061 pBXC3H His 10 C DM Xray-NM 2014
4RNG T. yellowstonii SemiSWEET in occluded state 3× 2 88 BL21(DE3) pET21b His 6 C DDM Xray-DDM 2014
4U9L T. thermophilus Mg2+transporter (MgtE) 5× 2 179–450 C41(DE3) pET His 6 N DDM Xray-DDM 2014
4CZB M. jannaschii Sodium proton antiporter
(Mjnhap1)
13 426 BL21(DE3) pET21a None C FC12 Xray-Cymal5 2014
2MMU M. tuberculosis Cell division protein (CrgA) 2 101 BL21(DE3) CodonPlus pET29b His 6 C Empigen ssNMR-
POPG/POPC
2014
2MIC R. norvegicus Neurotrophin receptor (p75) 1× 2 41 Cell-free expression NS5 NT9 Cell-free expression
pellet-sarkosyl
lsNMR-FC12 2014
4O93 T. thermophilus Nicotinamide nucleotide
transhydrogenase
3+ 9 94+270 BL21(DE3) pET21a His 6 N or C DDM Xray-DDM
(LCP)
2014
4RYQ B. cereus Translocator protein (TSPO) 5 181 BL21(DE3) pMCSG7 His 10 N DDM Xray-DDM
(LCP)
2015
4UC1 R. sphaeroides Translocator protein (TSPO) 5 158 BL21(DE3) pRK415 (lac) His NS5 NS5 DDM Xray-DM
(LCP)
2015
4TSY A. fragacea Haemolytic fragaceatoxin C
(FraC)
1× 8 179 BL21(DE3) pBAT-4 NT9 None Xray-DDM 2015
4XTL D. eikasta Rhodopsin 2 (KR2) 7 288 SE1 pSCodon1.2 His 6 C DDM Xray-DDM 2015
3X3B D. eikasta Rhodopsin 2 (KR2) 7 290 C41(DE3) pET His 6 C DDM Xray-DDM 2015
4YMS C. subterraneus Amino acid ABC transporter (Art
(QN)2)
5× 2 240+220 C43(DE3) pACYCDuet His 6 C DDM Xray-
CHAPSO
2015
4R0C A. borkumensis Transporter (YdaH) 9 492 BL21(DE3) ΔacrB pET15bΩydaH His 6 N DDM Xray-MD6 2015
4WOL H. sapiens Signaling module (DAP12) 1× 3 33 BL21(DE3) pMM His-trpLE 9 N IB-gua+TX100 Xray-None
(LCP)
2015
4YCR H. influenzae Anion channel (SLAC1) 10 328 C43(DE3) pWaldoGFPe His 8 C NF7 Xray-OG 2015
4W6V Y. enterocolitica Dipeptide transporter (PepT) 14 519 BL21(DE3) pLysS pZUDF21 His 10 C DDM Xray-DDM 2015
4RY2 R. thermocellum ABC transporter (PCAT1) 6× 2 730 BL21(DE3) CodonPlus pMCSG7 GST N DDM Xray-
CHAPSO
2015





BL21(DE3) Gold pLysS pET21b His 10 C DDM Xray-MD6 or
Cymal 6
2015
4QI1 H. walsbyi Bacteriorhodopsin-I 7 262 C43(DE3) pET21d His 6 C DDM Xray-DM 2015
5C78 C. jejuni Flippase (PglK) 6× 2 564 BL21(DE3) Gold pET19b His 10 N DDM Xray-DDM 2015
4Y7K M. acetivorans Mechanosensitive channel of
large conductance (MscL)
2× 5 275 C41(DE3) pET15b His 6 N TX100 Xray-MD6 2015
5A40 B. pertussis F−ion channel homologue (Fluc) 4× 2 128 BL21(DE3) pASK-IBA2 His 6 C DM Xray-DM
(LCP)
2015
5C8J M. jannaschii YidC-like protein (MJ0480) 4 198 BL21(DE3) pET28a His 6 C DDM Xray-DDM 2015
5DA0 D. geothermalis Proton-coupled fumarate
symporter (SLC26)
14 499 MC1061 pBXC3GH GFP+His 10 C DM Xray-DM or
NM
2015
5C6P N. gonorrhoeae MATE transporter (NorM) 12 459 BL21(DE3) pET15b His 10 C DDM Xray-DDM 2015
4XU4 M. vanbaalenii Insig homologue (MvINS) 6× 3 210 BL21(DE3) pET21b His 6 C LDAO Xray-OG 2015
5AYN B. bacteriovarus Fe2+ transporter (SLC40A1) 12 432 C41(DE3) pWaldo-GFPe GFP+His 8 C DDM Xray-LMNG
(LCP)
2015
5D91 R. Salmoninarum Phosphatidylinositolphosphate
synthase
6 336+Af2299 BL21(DE3) pLysS pMCSG7 His 10 N DDM Xray-DDM 2015
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Table 2 (continued)
PDB Organism Name TM1 Length Strain(s) Vector Tag Size N/C2 Solubilization3 Structure4 Date




BL21(DE3) pACYC-Duet His 6 C DDM Xray-DDM
(LCP)
2015







2× 4 318 BL21(DE3) pLysS pMCSG7 His 6 N DM Xray-DM 2016
5BZ3 T. thermophilus Sodium/proton antiporters
(NapA)
12 385 Lemo21 (DE3) pWaldo GFP+His 8 C DDM Xray-NM
(LCP)
2016
5A1S S. enterica Citrate symporter CitS 11 448 C41(DE3) pET21d His 10 N DM Xray-MD6 2016
5EZM C. metallidurans Glycosyltransferase (ArnT) 13 575 BL21(DE3) pLysS pNYCOMPS His 10 N DDM Xray-DDM
(LCP)
2016
3JCF T. maritima Mg2+transporter (CorA) 2× 5 351 BL21(DE3) pLysS pET15b His 6 N DDM EM-DDM 2016
2N2A H. sapiens Receptor tyrosine kinases (HER
or ErbB)
1× 2 58 Cell-free expression pGEMEX-1 NT9 Cell-free expression
pellet-sarkosyl
lsNMR-FC12 2016














8 C DDM Xray-DDM 2016
5EC1 S. lividans Potassium channel mutant
(KcsA)
2× 4 160 BL21(DE3) NS5 His 6 N FC12 or DM Xray-DM 2016
5AZD T. thermophilus Thermophilic rhodopsin (TR) 7 268 BL21(DE3) pET21c His 6 C DDM Xray-DDM 2016
2N7Q H. sapiens Human nicastrin 1 54 NS5 pET29b His 6 N IB-urea lsNMR-SDS
or FC12
2016
5ID3 C. elegans Mitochondrial calcium uniporter 2× 5 159 BL21(DE3) pET21a His 6 C FC14 lsNMR-FC14 2016
5JSZ L. delbrueckii Folate ECF transporter (FolT) 6 265 MC1061 p2BAD His 10 N DDM Xray-DDM 2016
2N4X A. fulgidus Electron transporter (Ccd(A)) 6 208 C43(DE3)-SEN212 pET28 His 6 C FC12 lsNMR-FC12 2016
5IWS B. cereus EIIC maltose transporter MalT 10 545 NS5 pMCSG28 His 6 C DDM Xray-DDM 2016
5I20 S. novella Aromatic amino acid exporter
(YddG)
10 287 Rosetta™ 2(DE3) pET His 8 C DDM Xray-DDM
(LCP)
2016




HIV-1 envelope spike (Env) 1× 3 40 BL21(DE3) pMM-LR6 His-trpLE 9 N IB-gua NMR-DMPC/
DHPC
2016
5G28 N. marinus Chloride-pumping rhodopsin
(ClR)
7 275 BL21(DE3) CodonPlus pET21b His 6 C DDM Xray-DDM 2016
5B57 B. cenocepacia ABC heme importer (BhuUV) 10×2 385 C41(DE3) pET19b His 8 N DM or NG Xray-NG 2016
5KTE D. radiodurans Transition-metal ion transporter
(NRAMP)
11 436 C41(DE3) pET21 His 8 N DDM Xray-MD6 2016
5T77 T. africanus MOP flippase (MurJ) 14 475 C41(DE3) pET26 MBP+His
and His
10 C DDM Xray-DMNG
(LCP)
2016
5MKK T. thermophilus ABC transporter (TmrAB) 6+ 6 611+577 BL21(DE3) pET22b His 10 C DDM Xray-Cymal5 2017
5ITE H. walsbyi Bacteriorhodopsin 7 268 C43(DE3) pET28b His 6 C DDM or SMA Xray-OG or
SMA (LCP)
2017
5FGN N. meningitidis Lipid A transferase 5 544 BL21(DE3) pLysS pTrc99A His 6 C DDM Xray-MD6 2017
5KTF M. musculus high density lipoprotein (HDL) 2 73 BL21(DE3) CodonPlus pQE30 His 8 N Empigen lsNMR-LPPG 2017
5L22 A. aeolicus ABC transporter (AaPrtD) 6× 2 572 NS5 NS5 His 6 C NS5 NS5 2017




C43(DE3) pQLink His 6 C DDM Xray-MD6 2017
5V4S L. licerasiae Cyclic nucleotide-gated channel
(LliK)
7 465 C43(DE3) pET His 8 N LMNG EM-LMNG 2017
5UNI T. thermophilus Nicotinamide nucleotide
transhydrogenase (TH)
3+ 9 94+261 BL21(DE3) NF7 NF7 NF7 NF7 NF7 2017
5XAM D. radiodurans Protein-export enhancer (SecDF) 10 740 BL21(DE3) pTV118N (lac) His 8 C DDM Xray-DDM 2017
5KHN B. multivorans Hopanoid transporter (HpnN) 12 877 BL21(DE3) pET15bΩhpnN His 6 C DDM Xray-DDM 2017
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Table 2 (continued)
PDB Organism Name TM1 Length Strain(s) Vector Tag Size N/C2 Solubilization3 Structure4 Date
5WUC S. acidocaldarius Trimeric intracellular cation
(TRIC)
7× 3 237 BL21(DE3) pLysS pET His 10 C DDM Xray-DM 2017
5VRE C. minutus Lysosomal K+ channel 6× 4 203 BL21(DE3) pET15b His 6 N DDM Xray-DMNG 2017
5WUF C. psych-rerythraea Trimeric intracellular cation
(TRIC)
7× 3 249 BL21(DE3) pLysS pET His 10 C DDM Xray-DM 2017
5T0O C. jejuni Multi-drug efflux transporter
(CmeB)
12 1040 BL21(DE3) pET15bΩcmeB His 6 N Cymal6 Xray-Cymal6 2017
5GKO A. baumannii ABC transporter (MacB) 4x2 671 BL21(DE3) pET22 His 6 N UDM Xray-UDM 2017
5LIL A. actinomy-
cetemcomitans
ABC transporter (MacB) 4x2 664 C43(DE3) pET28 His 6 N LMNG Xray-LMNG 2017
Beta-barrel
1PFO C. perfringens Perfringolysin-O 4 500 JM109 pRT10 His 6 N None None 1998
1H6S, 1BH3 R. blastica Porin (E1M/A116K) 16×3 307 BL21(DE3) pLysS pET3b NT9 LDAO Xray-C8E4 1998
1UYN H. influenzae Autotransporter (trimeric Hia) 12 308 BL21(DE3) pET11a NT9 IB-urea Xray-C10E5 2004
3O44, 1XEZ V. cholerae Pore-forming toxin (Cytosolin) 14 741 Origami B pHis-parallel2 His 6 N C10E6, None Xray-C10E6
or OG
2005
2GR8 H. influenzae Trimeric autotransporter (Hia) 4× 3 99 B834 pASK-IBA12 Strep N Elugent Xray-C8E4 2006
2ODJ P. aeruginosa Channel (OprD) 18 443 C43(DE3) pBAD22 His 6 C MD6 Xray-C8E4 2007
2VDF N. meningitidis OM adhesin (OpcA) 10 253 AR58 pMG1 NS5 LDAO Xray-C10E5 2007
2QTK P. aeruginosa Benzoate channel (OpdK) 18 390 C43(DE3) pBAD22 His 8 C LDAO Xray-C8E4 2008
2K4T H. sapiens Anion channel (VDAC-1) 19 291 BL21(DE3) pET21a His 6 C IB-urea lsNMR-LDAO 2008
2JK4 H. sapiens Voltage-dependent anion
channel (VDAC)
19 294 M15 NS5 PDS56 His 6 C IB-gua Xray-Cymal5 2008
3EMN,4C69 M. musculus Anion channel (VDAC-1) 19 295 M15 pQE9 His 6 N IB-gua Xray-LDAO
(bicelles)
2008
3DWO P. aeruginosa Fatty acid transporter (FadL) 14 451 C43(DE3) pBAD22 His 6 C LDAO Xray-C8E4 2008
2K0L K. pneumoniae OuterMP (OmpA) 8 216 BL21(DE3) pET21c His 6 C IB-gua lsNMR-
DHPC
2008
3CSL S. marcescens Heme receptor complex (HasR) 22 865 MC4100 pFR2 NT9 SB3-14 Xray-C8E4 2009
3FID S. typhimurium Lipid A deacylase (LpxR) 12 319 BL21(DE3) Star pET21a NT9 IB-urea Xray-C10E5 2009
3EFM B. pertussis OM transporter (FauA) 22 707 BL21(DE3) pET20b His 6 Oth8 OPOE Xray-C8E4 or
C8E5
2009
3D5K P. aeruginosa Outer MP (OprM) 4× 3 485 C43(DE3) pB22 His 8 C LDAO Xray-C8E4 2009
3FHH S. dysenteriae Heme/hemoglobin OM receptor
(ShuA)
22 640 BL21(DE3) pET20b His 6 Oth8 OPOE Xray-C8E4 or
C8E5
2009
3KVN P. aeruginosa Autotransporter (EstA) 12 646 C43(DE3) +
BL21(DE3) Star
pB22 His 7 N LDAO Xray-C8E4 2010
2X55 Y. pestis OM protease (omptin) 10 293 C43(DE3) pB22 His 6 C LDAO Xray-C8E4 2010
4QKY, 3NJT B. pertussis Transporter FhaC 16 554 BL21(DE3) omp5 pET24d His 6 N OG Xray-OG 2010
2X27 P. aeruginosa Outer MP G (OprG) 8 233 C43(DE3) pBAD His 6 C MD6 Xray-C8E4 2010
3ANZ S. aureus α-hemolysin 2× 7 302 B834(DE3) pET28b His 6 C None None 2011
3NSG S. typhi Porin (OmpF) 16 341 GJ1158 pET20b NT9 IB-urea Xray-LDAO 2011
3RBH P. aeruginosa Export protein (AlgE) 18 479 BL21(DE3) CodonPlus pET28a His 6 N DM Xray-OTOE 2011





S. aureus γ-hemolysin: (LukF) and (Hlg2) 16 309+290 B834(DE3) pET26+pRAREII His 6 N None None 2011
3QRA Y. pestis Adhesion protein (Ail) 8 157 BL21(DE3) pET16b NT9 IB-gua Xray-C8E4 2011
3SY7, 3SY9,
3SYB




P. aeruginosa Aromatic hydrocarbon (OccK3,
OpdO)
18 401 BL21(DE3) pB22 His 6 N MD6 Xray-C8E4 2012
3SZD P. aeruginosa Channel (OccK2, OpdF) 18 405 BL21(DE3) pB22 His 6 N MD6 Xray-C8E4 2012
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Table 2 (continued)
PDB Organism Name TM1 Length Strain(s) Vector Tag Size N/C2 Solubilization3 Structure4 Date
3SY9, 3SYS P. aeruginosa OM carboxylate channels (Occ) 18 430 BL21(DE3) pB22 His 6 N MD6 Xray-C8E4 2012
3V8X N. meningitidis Transferrin (TbpA) 22 915 BL21(DE3) pET20b His 10 N Elugent Xray-C8E4 2012
4E1T Y. pseudo-
tuberculosis
Invasin beta-domain 12 245 BL21(DE3) pET9 His 10 N Elugent Xray-MD6
(LCP)
2012
4GEY P. putida Carbohydrate transporter (OprB) 16 436 BL21(DE3) pBAD22 His 7 N Elugent Xray-C8E4 2012





3VZT N. meningitidis OM protein (PorB) 16 355 BL21(DE3) pET21b His 6 C IB-urea Xray-TDDG 2012
4AFK, 4XNL P. aeruginosa Export protein (AlgE) 18 458 BL21(DE3) pET200 NS5 OG Xray-LDAO
(LCP)
2013
4K3C H. ducreyi β-barrel assembly machinery
(BamA)
16 532 BL21(DE3) pET20b His 10 NS5 Elugent Xray-C8E4
(bicelles)
2013
4HSC S. pyogenes Streptolysin O pore-forming
toxin
4 571 XL1-Blue NF7 NF7 NF7 NF7 2013
4BUM D. rerio Voltage-dependent anion
channel 2
19 289 M15 pQE60 His 6 C IB-gua Xray-LDAO 2014
4PR7 D. dadantii OM porin (KdgM) 12 222 BL21(DE3) omp8 pLysS pKSM717 His 6 C OPOE Xray-C8E4 2014






His 6 C SB3-14 Xray-OG 2014
4Q35 S. flexneri Lipopolysaccharide transport
(Lpt)
26 802 (LptD) +
175(LptE)
BL21(DE3) pBAD22 His 6 C LDAO Xray-C8E4 2014
4MT0 N. gonorrhoeae OM multidrug efflux pump
(MtrE)
4 467 C43(DE3) pBAD22bΩmtrE His 6 C DDM Xray-MD6 2014
3J9C B. anthracis Protective antigen (PA-63) 14 562 BL21(DE3) pET22b-PA NT9 None EM-Igepal 2015
4MKO P. entomophila β-barrel pore-forming toxins (β-
PFT),
2 236 Rosetta™ 2(DE3) pLysS pETG-20A TrxA-His 6 N None None 2015
4RL9 A. baumannii Carbapenem-associated OM
protein
8 255 BL21(DE3) and
C43(DE3)
pET15, pB22 His 6 N or C IB-urea Xray-C8E4 2015
4V3G K. oxytoca OM protein (CymA) 14 339 C43(DE3) ΔcyoABCD pB22 His 7 N Elugent Xray-C8E4 2015
2N2M Y pestis Attachment invasion locus (Ail) 8 156 NF7 NF7 NF7 NF7 NF7 NS5 lsNMR-DePC 2015
4RL8 P. putida OM channel (COG4313) 12 275 C43(DE3) pB22 His 6 C IB-urea Xray-C8E4 or
MD6
2015
5BUN S. enterica Antigenic OM protein 12 467 BL21(DE3) pHDST His NS5 NS5 DDM Xray-DDM 2015




5DL7 A. baumannii OM carboxylate channel
(OccAB3)
18 419 C43(DE3) pB22 His 7 N Elugent Xray-C8E4 2016
5DL5 A. baumannii OM carboxylate channel
(OccAB1)
18 430 C43(DE3) pB22 His 7 N Elugent Xray-C8E4 2016
5DL6 A. baumannii OM carboxylate channel
(OccAB2)
18 413 C43(DE3) pB22 His 7 N Elugent Xray-C8E4 2016
5DL8 A. baumannii OM carboxylate channel
(OccAB4)
18 407 C43(DE3) pB22 His 7 N Elugent Xray-C8E4 2016
5GAQ E. fetida β-pore-forming toxins (β-PFTs) 2 310 Rosetta™ 2(DE3) pHis-Parallel1 His 6 C None EM-DDM 2016
5IXM Y. pestis Lipopolysaccharide transport
(Lpt)
26 577 (LptD) +
198 (LptE)
BL21(DE3) pET9 /pCDFc1b His 10 and 6 N and C Elugent Xray-C8E4 2016




BL21(DE3) pET9/pCDFc1b His 10 and 6 N and C Elugent Xray-C8E4 2016
5IVA P. aeruginosa Lipopolysaccharide transport
(Lpt)
26 646 (LptD) +
192 (LptE)
BL21(DE3) pET9/pCDFc1b His 10 and 6 N and C Elugent Xray-C8E4 2016
5AZO, 5AZS P. aeruginosa Multidrug efflux pump (OprN-J) 12 455 C43(DE3) pET21b His 6 C TX100 NF7 2016
5FVN E. cloacae Porin (OMPs) 16 342 BL21(DE3) omp8 pBAD24 NT9 LDAO Xray-C8E4 2016
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Rosetta™ 2(DE3) (Table 7). The bacterial host BL21(DE3) (including
mutant derivatives) is most used (111 uMPS), followed by the two
mutant hosts, C43(DE3) and C41(DE3) (54 and 30 uMPS, respectively).
The BL21(DE3) host together with plasmids expressing either lysozyme
or a rare tRNA (28 and 19 uMPS) follows in fourth and fifth position,
respectively. Rosetta™ 2(DE3) was used for a total of 13 uMPS. Bacterial
hosts other than those mentioned above have only had a marginal
impact in the field (1 to 8 uMPS each). Production of homologous
membrane proteins in E. coli shows a similar pattern (Table 8), although
native E. coli promoters were more frequently used (Fig. 5). As ex-
pected, rare tRNA plasmids were not typically used for the production
of homologous membrane proteins. The two most used bacterial hosts
were BL21(DE3) and C43(DE3) yielding 41 and 26 uMPS, respectively
(Table 8). Table 9 lists the genotypes of the bacterial hosts identified in
this analysis.
Expression systems that are not T7RNAP-based do not require
λDE3-containing hosts. Despite this, it is noticeable that in the case of
the ara expression system, C43(DE3) is used more than any other strain:
16 out of 47 non-E. coli uMPS and 5 out of 12 E. coli uMPS were pro-
duced in C43(DE3). Whether the lacI super-repressor mutation or an-
other mutation found in this host [12] is advantageous for the regula-
tion of the arabinose promoter remains to be demonstrated.
The T7RNAP-based expression system in combination with
C41(DE3) or C43(DE3) has been mostly used to produce α-helical
membrane proteins, while BL21(DE3) and other BL21(DE3) derivatives
were also used to produce β-barrel membrane proteins. The situation is
opposite for the arabinose expression system where C43(DE3) hosts
produced mainly β-barrels. In the T7RNAP-based expression system,
C41(DE3) and C43(DE3) hosts were more frequently used for uMPS
containing more than 7 transmembrane domains, while BL21(DE3) was
preferentially used for smaller proteins, typically with 1–2 transmem-
brane domains (Tables 1 and 2).
It is clear that selecting the optimal combination of promoter, tag
and bacterial host is key to achieving suitable recombinant membrane
protein yields for biophysical studies. In order to provide some gui-
dance, in our experience the following applies to the T7RNAP-based
expression system with the C41(DE3) and C43(DE3) bacterial strains,
which were originally derived using high copy number plasmids
(200–600 copies/cell, such as those containing the pMB1 origin of re-
plication). A non-exhaustive list of suitable plasmids includes pMW7
and derivatives (pHis and pRun) [13,14], pGEM (Promega), pRSET and
pDEST (Invitrogen), pIVEX (5prime) and pPR-IBA (IBA). It is important
to note that the chosen plasmid should not contain lacI or lacO se-
quences because further attenuation of the T7 promoter is often not
needed for those expression hosts (see also comments on stability
testing in Section 3). For BL21(DE3) derivatives, medium copy number
vectors (pET series) and those containing lacI and lacO sequences (e.g.
pET 3, 9, 14, 17, 20 or 23 from Novagen) are more suitable because
they reduce the amount of T7RNAP before induction. Use of the com-
panion plasmid pLyS inhibits T7RNAP after induction. The BL21AI
host, which contains the T7RNAP gene under the control of the arabi-
nose promoter or the Lemo21 host [15], which contains a companion
plasmid expressing the lysozyme gene under the control of the rham-
nose promoter, may also be useful to titrate the amount or activity of
T7RNAP.
2.4. Promoter usage for yeast expression
Table 10 lists the yeast promoters and strains that are integral
components of yeast expression systems. Table 11 lists the corre-
sponding genotypes. Typically, episomal plasmids are used for expres-
sion in S. cerevisiae, while the expression cassette is integrated into the
genome of P. pastoris. This situation probably results from the re-
production of early successes with these combinations. Since the P.
pastoris system depends upon very strong promoters, only a few copies
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Table 3
Unique membrane protein structures derived from recombinant proteins produced in Pichia pastoris.
PDB Organism Description TM1 Size Host Vector Tag L2 N/C3 Solub4 Struct5 Date
Monotopic
1GOS, 1OJA H. sapiens Monoamine oxidase B (MAO) 0 520 KM71 pPIC3.5 K NS6 None Xray-LDAO or
SB3-12
2001
2BXR H. sapiens Monoamine oxidase A (MAO) 0 527 KM71 pPIC3.5 K NS6 None Xray-OG 2005
Alpha-helical
2A79, 3LUT R. norvegicus Voltage-dependent potassium ion
channels (kV channels)
6× 4 333 SMD1163 (HIS+) pPICZC His 8 N DDM Xray-DM 2005
1Z98, 3CLL S. oleracea Plant aquaporin 7 281 X33 pPICZB His 6 C OG Xray-OG 2005
2UUH, 4JCZ H. sapiens LTC4 synthase 4× 3 156 KM71H pPICZA His 6 N MD7 Xray-DDM 2007
2R9R, 3LNM R. norvegicus Voltage-dependent K1 channels (kV) 6× 4 514+333 SMD1163 (HIS+) pPICZ-C His 10 N DDM Xray- MD7 2007
3D9S H. sapiens Human aquaporin 5 6 266 X33 pPICZ-B NT8 NG Xray-NG 2008
3G5U, 4M1M, 4Q9H M. musculus P-glycoprotein (Pgp) 12 1284 GS115 pHIL-D2 His 6 C TX100 Xray-DDM 2009
3GD8 H. sapiens Aquaporin (AQP) 4 6 223 X33 pPICZ His+ FLAG 8 N OG Xray-OG 2009
2W2E, 3ZOJ P. pastoris Yeast aquaporin 6 279 GS115-his4 pPICZαB His 6 C OG Xray-OG 2009
3JYC, 3SPI G. gallus Inward-rectifier potassium channels 2× 4 343 SMD1163 (HIS+) pPICZB GFP C DM Xray-DM 2010
3RZE H. sapiens Histamine-H1 receptor (H1R) 7 452 SMD1163 pPIC9K GFP+His 8 C DDM Xray-DDM 2011





3VG9 H. sapiens A2A adenosine receptor (A2AAR) 7 326 SMD1163 pPIC9K His+ FLAG 10 C DDM Xray-DDM 2012
3UM7, 4I9W, 4WFF H. sapiens Potassium channel K2P4.1 (TRAAK) 4× 2 309 SMD1163 pPICZB GFP+His 10 C DDM Xray-FC12 2012
3UKM H. sapiens Two–pore domain potassium (K+)
channels (K2P channels)
4× 2 280 SMD1163 (HIS+) pPICZC GFP+His 10 N DDM Xray- MD7 2012
4F4C C. elegans P-glycoprotein (P-gp) 12 1321 SMD1163 pPICZ and pVL1393 GFP+His 10 C DDM Xray-UDTM 2012
4HKR D. melano-gaster Calcium release- activated calcium
channel Orai
4× 6 214 SMD1163 (HIS+) pPICZC His 6 C DDM Xray- MD7 2012
3WME C. merolae P-glycoprotein 6× 2 612 SMD1163 pPICZA His 10 C C12E9 Xray-DM 2014
4NEF H. sapiens Human aquaporin 2 (AQP2) 6 242 GS115 aqy1Δ pPICZB His 8 N NG Xray-OGNG 2014
4RDQ, 5T5N G. gallus Bestrophin calcium-activated chloride
channels (CaCCs)
4× 5 409 SMD1163 (HIS+) pPICZ Anti-tubulin Ab 5 C DDM Xray-DDM 2014
5CTG O. sativa SWEET transporters 7 224 pPICZC GFP+His C DDM Xray-NG 2015
5E1J, 5TUA A. thaliana Two-pore channels (TPCs) 12× 2 741 SMD1163 pPICZ GFP+His 8 C DDM Xray-LMNG 2015
5I32 A. thaliana Aquaporins of the TIP subfamily 6 275 X33 pPICZB His 10 N OG Xray-OG 2016




12 C DDM Xray- MD7 2016
5KUK G. gallus Inward rectifier potassium (Kir) channel 2× 4 343 SMD1163 (HIS+) pPICZB Flag C DM Xray-DM 2016
5EGI C. elegans Trimeric intracellular cation (TRIC)
channel family
7× 3 257 GS115 pPICZA/C His 6 C TX100 Xray-DM 2016
5U1D H. sapiens ABC transporter 6+ 6 748+686 + 88 SMD1163 (HIS+) pPICZ Protein A C EM- MD7 2017
5VK5 M. musculus Potassium (K2P) channels of the TREK
subfamily
4 312 SMD1163H pPICZ GFP+His 10 C MD7 Xray- MD7 2017
5WIE R. norvegicus Voltage-gated K+ channels (kV) 6× 4 (532)+ β-subunit
(333)
SMD1163 (HIS+) pPICZB Strep × 2 N DDM Xray- MD7 2017
5XJJ C. sativa Multidrug and toxic compound extrusion
(MATE)
12 455 NF9 NF9 NF9 NF9 NF9 NF9 NF9 2017
1 Number of transmembrane domains.
2 Tag length.
3 N- or C-terminal position.
4 Solubilization detergent.
5 Detergent used for structure determination.
6 Not specified in PDB or corresponding publication.
7 Mixed detergent.
8 No tag.
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obtain sufficient levels of mRNA, although it is apparent that copy
number and protein yield are not linearly correlated. The negative
impact of secretory stress and clonal instability are areas on which in-
vestigators have focussed attention in the search for productive re-
combinant P. pastoris strains [16]. A recent report has streamlined the
‘time-to-strain pipeline’ in P. pastoris [17]. In contrast, in S. cerevisiae,
the promoter may be 10- to 100-fold weaker, so the use of episomal
plasmids with high copy numbers is advantageous; episomal plasmids
are available for P. pastoris [18], but are not yet widely used in struc-
tural biology projects.
The strong S. cerevisiae promoter, PGAL1, is induced with galactose
while PAOX1 (a very strong P. pastoris promoter) is induced with me-
thanol [19]. In choosing a strong promoter, the idea is that transcrip-
tion should not be rate limiting. However, high mRNA synthesis rates
may be countered by high rates of mRNA degradation [20]. Evidence
from bacterial expression systems suggests that lowering promoter ef-
ficiency via mutation can lead to improved functional yields of mem-
brane proteins for some, but not all, targets [21]. It has been proposed
that the ideal inducible system would completely uncouple cell growth
from recombinant synthesis, which requires the host cell to remain
metabolically capable of transcription and translation in a growth-ar-
rested state. In this scenario, all metabolic fluxes would be diverted to
the production of recombinant protein [22]. While this approach is yet
to be demonstrated for membrane protein production in yeast cells,
soluble chloramphenicol acetyltransferase was produced to more than
40% of total cell protein in E. coli [23] suggesting that this may be a
strategy worth exploring in yeast. As for bacteria, yeast growth rates
often (but not always) decline dramatically upon induction of yeast
cultures, in part achieving this state.
3. Bacterial expression systems for membrane protein production:
PT7-based expression protocols
3.1. Optimization of culture growth conditions for improved membrane
protein production
We have previously examined the importance of optimizing growth
conditions for improved membrane protein production in bacterial host
cells [24,25] and have published an analysis of the T7RNAP-based
expression system [8]. Here we combine these insights with our up-
dated analysis of the PDB. For simplicity, we refer only to the T7RNAP-
based expression system in this section, but the principles of most of our
advice can be applied more widely to other microbial expression hosts.
An important, but simple, test that should be done prior to culturing
recombinant strains is to assess whether the selected plasmid/bacterial
host combination is stable over time in the medium to be used for large-
scale production. We suggest assessing individual cultures from five
independent colonies. After overnight growth in the presence of a sui-
table antibiotic, 10−6, 10−7 and 10−8 dilutions should be plated on
2∗TY agar with and without antibiotic. If the same number of colonies
is obtained in the absence or presence of antibiotic, then the plasmid is
stable and it is appropriate to proceed to growing large-scale cultures.
However, if the number of colonies is higher in the absence of anti-
biotic, the expression plasmid is unstable (even prior to inducing ex-
pression of the target gene), and it is not advisable to prepare a large-
scale culture. In this scenario, it would be prudent to change to a better
regulated host strain such as C41(DE3), C43(DE3), Lemo21(DE3) or
BL21(DE3) pLysS. Alternatively, some investigators do not plate cells
after heat shock but use the whole transformation medium as a pre-
culture [26]. By doing this, they take advantage of the significant
variability in target gene expression level from one colony to another,
in the hope of achieving a reasonable recombinant protein yield.
In general, however, it is preferable to start from freshly-trans-
formed bacterial cells. A typical approach is to inoculate 5ml 2∗TY
medium with an isolated colony and incubate overnight. The next
morning, this should be used to inoculate 500ml of 2∗TY medium in a
2.5 L flask. The culture should reach an optical density of 0.6 in fewer
than 5 h; if not, then the basal expression level of the target gene must
be impairing cell growth, which usually affects the stability of the ex-
pression plasmid. Instead of the typical induction protocol (0.7 mM
IPTG at A600=0.6), two options are also worth trying. The first is not
to add IPTG and instead to let the culture grow overnight at 30 °C or
37 °C. This protocol works well for high copy number plasmids that are
not regulated (i.e. they lack the T7lac promoter and/or multicopy lacI
or lysozyme gene expression); two membrane protein structures were
obtained without inducing the culture in this way [27,28]. The second
method is to add IPTG at the beginning of the stationary phase
(A600=1) either in trace amounts (10 μM) following the improved
protocol of Alfasi and colleagues [29] or at a high concentration
(0.7 mM) in the stationary phase (Table 12). However, adding IPTG in
the stationary phase is not recommended when using C41(DE3) or
C43(DE3) and will result in decreased expression levels of the target
gene.
3.2. Selection of mutant T7RNAP-based expression strains for toxic genes
C41(DE3) and C43(DE3) were originally selected as part of a
strategy to produce a membrane protein target that was toxic to
BL21(DE3) host cells [30]. The protocol summarized here allows the
selection of a bacterial strain to produce any given toxic target mem-
brane protein. Having a reporter gene such as GFP makes the experi-
ment faster but is not essential; C41(DE3) and C43(DE3) were selected
without the use of a fluorescent reporter.
The expression plasmid containing the gene of interest should be
transformed into BL21(DE3) using calcium chloride and with 1–10 ng
of plasmid. After incubation of the 1ml transformation culture for 1 h at
37 °C, 100 μl are spread onto a 2∗TY plates with antibiotic and onto
2∗TY plates with antibiotic supplemented with either 0.4 mM or
0.7 mM IPTG (this range avoids the non-specific toxicity of IPTG above
0.7 mM). If the vector expressing the target membrane protein does not
prevent cell growth on IPTG-containing plates, mutant strains cannot be
selected. If there are hundreds of colonies in the absence of IPTG but
very few in the presence of IPTG, some mutants may appear at high
frequency.
Typically, five selection experiments can be performed in one day:
five 250ml flasks containing 50ml 2∗TY medium with antibiotic are
each inoculated with one bacterial colony. Once the culture has reached
A600=0.4–0.6, IPTG is added at 0.7 mM final concentration to induce
gene expression. One to two hours after induction, 1ml culture is
harvested and serial 10−1 to 10−4 dilutions are plated onto the IPTG-
and antibiotic-containing plates. The frequency of appearance of mu-
tant hosts varies from 10−4 to 10−6 [30]. After an overnight incubation
at 37 °C, the number of colonies of different sizes is counted. Large
colonies have usually lost the ability to express the target gene in
contrast to small colonies, which arise at a frequency of 1–20%. Fig. 6
shows selection experiments with the green fluorescent protein (GFP) as
a reporter gene. Panel A shows the size difference between mutant hosts
under normal light while panel B shows the same plate under UV ex-
posure. Almost all the small colonies are green and therefore express
high amounts of GFP. Large colonies exhibit no or weak fluorescence.
Panel C shows a selection experiment where all colonies are small.
Among them, some exhibit very high fluorescence intensity. Panel D
shows another independent experiment where medium colonies are
fluorescent, while the very small ones are not. In the case where a GFP
reporter is not being used, membrane protein production can be as-
sessed by immuno-detection or by staining an SDS-PAGE gel with
Coomassie Brilliant Blue.
To check whether the mutation is within the bacterial genome of the
colony or the plasmid DNA, mutant colonies need to be cured of the
expression vector. The vector DNA can be isolated using standard
'miniprep' protocols, while the colony can be cured of the plasmid
through spontaneous loss in the absence of antibiotic (ten days were
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Table 4
Unique membrane protein structures derived from recombinant proteins produced in Saccharomyces cerevisiae.
PDB Organism Description TM1 Size Host Vector Tag L2 N/C3 Solub4 Struct5 Date
Alpha-helical
1O5W R. norvegicus Monoamine oxidase (MAO) 1 534 BJ2168 YEp51 His 6 N FC12 Xray-MD7 2004
2Z5X R. sapiens Monoamine oxidase (MAO) 1 513 BJ2168 YEp51 His 6 N FC12 Xray- MD7 2008
4A01 V. radiata H+ translocating pyrophosphatases
(H+ -PPases)
16 766 BJ2168 pYVH6 His 6 C DDM Xray-DM 2012
4AV3 T. maritima Pyrophosphatases (M-PPases) 16 735 BJ1991 pRS1024 His 6 N DDM Xray-OGNG or
Cymal5
2012
4IL3 S. mikatae CaaX protease Ste24p 7 461 BJ5460 pSGP46 His 10 C DDM Xray-C12E7 2013
4J05 P. indica Phosphate:H+ symporter (PHS) 12 530 DSY-5 p423-GAL1 His+ FLAG 10 C DDM Xray-NG 2013
4K1C S. cerevisiae Ca2+/H+ exchanger (VCX1) 11 421 DSY-5 p423-GAL1 His+ FLAG 10 C DDM Xray-DDM 2013




pYeDP60 BAD C C12E8 Xray-C12E8 2013
4C9G S. cerevisiae Mitochondrial ADP/ATP carrier 6 318 WB12 pYES3 His 8/9 N UDM Xray-DM or
Cymal5
2014
4LXJ S. cerevisiae Cytochrome P450 1 536 MMLY941 NS6 His 6 C DM Xray-DM 2014
4WIS N. haematococca Anoctamin family (TMEM16) 10× 2 735 FGY217
(Δura)
pYES2 GFP+His 10 N DDM Xray- MD7 2014
3J9T S. cerevisiae H+-ATPases (V-ATPases) (subunits
ABCDEFGHacc'c''d)
8a+ 40 cc'c'' 616+ 517 + 392+256 + 23+118F +
478+840a + 160 cc'c'' + 345d
JTY002 NS6 FLAG C DM EM-DDM 2015




pRS426GAL1 GFP+His 8 C DDM Xray-DDM 2015
5AEX S. cerevisiae (Mep2) 10 505 W303 (pep4Δ) p83νΔ His 6 C MD7 Xray-DMNG 2016
5AEZ C. albicans Mep2 proteins 11× 3 486 W303 (pep4Δ) p83νΔ His 6 C MD7 Xray-DM or NG or
OGNG
2016
5DQQ A. thaliana Two-pore channels (TPCs) 12× 2 723 DSY-5 p423-GAL1 His 10 C DDM Xray-DDM 2016
5HI9 R. norvegicus Transient receptor potential (TRP) 6× 4 770 BJ5457 pYepM 1D4 epitope C LMNG EM-DMNG 2016
5EQI H. sapiens Glucose transporter 1 (hGLUT1) 12 492 DSY-5 p423-GAL1 His 10 C DDM Xray-NG 2016
5I6C A. nidulans Uric acid/xanthine H+ symporter
(UapA)
14× 2 574 FGY217 pDDGFP GFP+His 8 C DDM Xray-DDM 2016




680a+ 150c + 147c' + 213c'' +
297d+57e + 54f
CACY1 NS6 FLAG C DM EM-DDM 2016
5LZQ T. maritima Pyrophosphatases (M-PPases) 16× 2 735 BJ2168 pYES2 His 6 C DDM Xray-DM 2016
5V6P S. cerevisiae (Hrd1-Hrd3) 8× 2 407 INVSc1 pRS42X Strep C DM EM-amphipol8 2017
1 Number of transmembrane domains.
2 Tag length.
3 N- or C-terminal position.
4 Solubilization detergent.
5 Detergent used for structure determination.
6 Not specified in PDB or corresponding publication.
7 Mixed detergent.
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required to cure C41(DE3) from the pOGCP expression plasmid [30]). If
the mutation is in the expression vector, transformation of the isolated
plasmid into BL21(DE3) cells should give colonies on IPTG-containing
plates; if there are no colonies, then the isolated colony carries the
mutation.
3.3. Expression of non-toxic or moderately-toxic target genes
Expression of genes encoding non-toxic or moderately-toxic mem-
brane proteins cloned in T7 expression plasmids lead to colony for-
mation on IPTG-containing plates. Toxicity is inversely proportional to
the size of colonies on these plates. We have observed that antibiotic
use is not required in large-scale cultures, providing that antibiotic has
been added to the preculture [24]. The induction protocol must be
adjusted depending on the size of the colonies on IPTG plates
(Table 12). If the size reduction is marginal compared to plates lacking
IPTG (<10%), this may suggest that the production yield of the target
membrane protein is very low. To maximize the chance of obtaining
high yields, 0.7 mM IPTG should be added at the early exponential
phase (A600≤ 0.4). If the size of the colonies is decreased by 10% or
more, then IPTG should be added at A600=0.6 at the two
concentrations that are most frequently used [8]: 0.4mM and 0.7 mM
(Table 12). Autoinduction has been used with the T7 and arabinose
expression systems ([31] and Table 2 in the cases of 4HYJ, 4KJS and
3FID). In E. coli, glucose is a catabolic repressor that is catabolized
before any other carbon source. Autoinduction media take advantage of
this; they contain glucose to allow the bacterial cells to grow to high
densities, but when the glucose has been exhausted, cells switch on
operons involved in the catabolism of the other carbon sources present.
Autoinduction media contain a defined amount of lactose that can bind
to lacI and stimulate the expression of T7RNAP. Commercial auto-
induction media are not cheap, but are a useful option when leaky
expression is toxic and prevents cell growth prior to IPTG addition.
Another option to circumvent toxicity is to decrease the temperature of
the culture 30min before IPTG addition. In a previous study [8], we
demonstrated that in approximately 50% of studies using T7 expression
systems, lowering the temperature (i) prevented the formation of in-
clusion bodies, (ii) improved the solubility of the recombinant mem-
brane protein, (iii) reduced toxicity or (iv) prevented overgrowth of the
culture by cells that had lost the expression plasmid [30].
3.4. Collecting proliferated membranes or inclusion bodies from E. coli
hosts
Formation of inclusion bodies containing a recombinant membrane
protein (IBMP) occurs frequently in bacteria especially for non-E. coli
targets. Inclusion body formation is usually not toxic to the cell, the
recombinant protein can be accumulated to very high levels and, in
some cases, the protein is in an ‘amyloid’ form which entraps functional
protein [4]. Bacterial inclusion bodies have been shown to sponta-
neously penetrate mammalian cells and can be targeted to specific re-
ceptors, opening the way to deliver functional drugs. Due to their
natural abundance and the fact that Ni2+-affinity chromatography can
be performed in denaturing conditions, IBMP can be purified in large
quantities. One application is their use as an alternative to peptides for
raising specific antibodies against eukaryotic proteins [5,6]. As men-
tioned in Section 2.1, large scale refolding of inclusion bodies has been
attempted in the field of structural biology and some progress has been
made especially for NMR analysis. For instance, several G protein-
coupled receptors (GPCRs) have been produced in a functional form
(after refolding of E. coli-produced inclusion bodies in amphipols [7,8])
Table 5
Number of unique membrane protein structures derived from recombinant









E. coli 144 0 0 144
Non-E. coli bacteria 237 0 2 239
Plant 2 5 3 10
Mammal 41 18 5 64
Bird 0 3 0 3
Virus 5 0 0 5
Fungus 4 1 12 17
Archaea 28 0 0 28
Parasite 2 0 0 2
Other1 5 4 0 9
Total2 468 31 22 521
1 Plexaura homomalla, Danio rerio, Eisenia fetida, Actinia fragacea,
Caenorhabditis elegans.
2 The PDB was analyzed in November 2017.
Fig. 1. Secondary structure analysis of recombinant membrane proteins pro-
duced in E. coli and yeast for which a structure has been resolved. Data were
obtained from Tables 1–4. The percentage of unique membrane protein struc-
tures is plotted as a function of their secondary structure for recombinant
membrane proteins produced either in yeast (grey) or E. coli (black).
Fig. 2. Size distribution of recombinant membrane proteins produced in E. coli
and yeast for which a structure has been resolved. Data were obtained from
Tables 1–4. The percentage of unique membrane protein structures is plotted as
a function of their amino acid content for recombinant membrane proteins
produced either in yeast (grey) or E. coli (black).
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Table 6
Unique eukaryotic membrane protein structures derived from recombinant proteins produced in E. coli.
PDB Organism Name TM1 Length Strain(s) Vector Tag Size N/C2 Solub3 Struct4 Date
Monotopic
1UUM R. rattus Flavin dihydroorotate dehydrogenase
(DHOD)
0 372 XL1-Blue Tetra pASKDr His 6 N None Xray-OG 2004
2PRM H. sapiens Dihydroorotate dehydrogenase
(DHODH)
0 367 BL21(DE3) T7 pET19b His 10 N TX100 Xray-MD5 2008
3O8Y H. sapiens Enzyme 5-lipoxygenase (5LOX) 0 691 Rosetta™ 2(DE3) T7 pET14b His 6 N None None 2011
4HHS A. thaliana Fatty acid α-dioxygenase (α-DOX) 0 652 M15 T5 pQE30 His 6 N DM Xray-NG 2013
4NRE H. sapiens Enzyme 15-lipoxygenase-2 (15LOX-2) 0 696 Rosetta™ 2(DE3) T7 pETDuet-1 His 6 N None None 2014
4PLA H. sapiens Phatidylinositol 4-kinase type IIa
(PI4K IIa)
0 556 BL21(DE3) Star T7 pRSFD His 6 N None None 2014
4QN9 H. sapiens Fatty-acid ethanolamides (FAEs) 0 393 Rosetta-origamiB (DE3)
pLysS; Other
pMAL MBP+His 6 C TX100 Xray-DC 2015
Alpha-helical
1ZLL, 2M3B H. sapiens Phospholamban homopentamer 1×5 52 BL21(DE3); Other pMALc2 x MBP N NS6 lsNMR-FC12 ssNMR-
DOPC/DOPE
2005
2HAC H. sapiens TCR-CD3, TM dimer complex 1×2 33 BL21(DE3) T7 pMM-LR6 His 9 N IB-gua8 + TX100 lsNMR-SDS/FC12 2006
2JO1 H. sapiens Phospholemman (FXYD1) 1 72 C43(DE3) T7 pETBcl-XL Bcl-XL+His 6 N IB-gua8 lsNMR-SDS 2007
2Q7M H. sapiens Lipoxygenase protein (FLAP) 4×3 161 BL21(DE3) T7 pET28a His 6 C DDM Xray-MD5 2007
2K1L H. sapiens Receptor tyrosine kinase (EphA1) 1 38 BL21(DE3) pLysS T7 pGEMEX1 TrxA-His NS6 N TX100 lsNMR-DMPC/DHPC 2008
3DWW H. sapiens Prostaglandin E synthase 1 4×3 158 BL21(DE3) pLysS T7 pSP19T7LT His 6 N TX100 EM-TX100 2009
2K9Y H. sapiens Receptor tyrosine kinases (Eph2) 1 41 BL21(DE3) pLysS T7 pGEMEX1 TrxA-His NS6 N TX100 lsNMR-MeOH/CHCl3/H2O 2009
2KNC H. sapiens Integrin αIIbβ3 1+1 54 and 79 BL21(DE3) Other pMAL-C2 MBP-His 6 N TX100 lsNMR-CD3CN/H2O 2009
2KOG R. norvegicus Synaptobrevin 1 119 BL21(DE3)/BL21(DE3) pRil
T7
pET15b/28a His 6 N Sodium cholate lsNMR-FC12 2009
2KS1, 2JWA H. sapiens ErbB1/ErbB2 1×2 44 BL21(DE3) pLysS T7 pGEMEX1 TrxA-His 6 N TX100 lsNMR-DHPC/DMPC 2010
2KPF H. sapiens Glycophorin A (GpA) 1×2 38 NF7 NF7 NF7 lsNMR-DHPC/DMPC 2010
2L35 H. sapiens Signaling module (DAP12) 2+1 63+32 BL21(DE3) T7 pMM-LR6 His-trpLE 9 N IB-gua8 + TX100 lsNMR-FC14+ SDS 2010
2KYV H. sapiens Phospholamban homopentamer 1×5 52 BL21(DE3) T7 pET MBP N TX100 lsNMR-FC12 ssNMR-
DOPE/DOPE
2011
2L9U H. sapiens Transmembrane domain (ErbB3) 1×2 40 Cell-free expression pET22b His 6 C Cell-free expression-pellet lsNMR-FC12 2011
2LCK M. musculus Mitochondrial uncoupling protein 2
(UCP2)
6 303 Rosetta™ 2(DE3) pET21 His 6 C FC12 FC12 2011
2LCX H. sapiens ErbB4 1×2 44 BL21(DE3) pLysS T7 pGEMEX1 TrxA-His 6 N TX100 lsNMR-DHPC/DMPC 2012
2LNL H. sapiens Receptor (CXCR1) 7 309 BL21(DE3) T7 pGEX2a GST+His 6 C IB-SDS ssNMR-DMPC 2012
2LOU H. sapiens Apelin receptor 1 64 BL21(DE3) T7 pEXP5-CT His 6 C IB- acetonitrile /trifluoracetic
acid
lsNMR-FC12 2013
2M6B H. sapiens Glycine receptor (hGlyR-α1) 4×5 150 BL21(DE3) pLysS T7 pET31b His 6 C IB-NS6 lsNMR-LPPG 2013
2LZL H. sapiens Growth factor receptor 3 (FGFR3) 1×2 43 BL21(DE3) pLysS T7 pGEMEX1 TrxA-His 6 N TX100 lsNMR-FC12/SDS 2013
2MAW H. sapiens Neuronal acetylcholine receptor 4 137 Rosetta™ 2(DE3) pLysS T7 pMCSG7 His 6 N NS6 lsNMR-LDAO 2013
2M8R, 3HD7 R. norvegicus Syntaxin 1A, TM & syntaxin complex 1+1 109+91 BL21(DE3) T7 pET28a His 6 N TX100 or OG lsNMR-FC12, Xray-NG or
C7G
2013
4BUO R. norvegicus Neurotensin receptor (NTS1) 7 335 BL21 Tuner Other pBR322 MBP+His 6 N MD5 Xray-MD5 2014
4O6Y A. thaliana Cytochrome B561 (Cyt b561-B) 6 230 BL21(DE3) T7 pET15b His 6 NS
6 DM Xray-NG 2014
2M59 H. sapiens Endothelial growth factor receptor 2 1 x 2 37 Cell-free expression pET20b HA N Cell-free expression pellet-TFE/
H2O/TFA
lsNMR-FC12 2014
2MGY M. musculus Translocator protein (TSPO) 5 169 BL21(DE3) pET15b His 6 N IB-SDS lsNMR-FC12 2014
2MFR H. sapiens Insulin receptor (AAs 940–980) 1 57 BL21(DE3) T7 pET29b His 6 C IB-urea lsNMR-FC12 2014
2MIC R. norvegicus Neurotrophin receptor (p75) 1×2 41 Cell-free expression NS6 NT9 Cell-free expression pellet-
sarkosyl
lsNMR-FC12 2014
4TSY A. fragacea Haemolytic fragaceatoxin C (FraC) 1×8 179 BL21(DE3) T7 pBAT-4 NT9 None Xray-DDM 2015
4WOL H. sapiens Signaling module (DAP12) 1×3 33 BL21(DE3) T7 pMM His-trpLE 9 N IB-gua8 + TX100 Xray-None (LCP) 2015
5EH4 H. sapiens Glycophorin A (GpA) 1×2 30 BL21(DE3) T7 pMM His-trpLE 9 N IB-gua8 + TX100 Xray-None (LCP) 2015
2N2A H. sapiens Receptor tyrosine kinases (HER or
ErbB)
1×2 58 Cell-free expression pGEMEX-1 NT9 Cell-free expression pellet-
sarkosyl
lsNMR-FC12 2016
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and successfully studied by high resolution NMR [9]. However, re-
folding of IBMP is challenging because some surfactants maintain
misfolded membrane proteins in solution, as exemplified by the mi-
tochondrial uncoupling protein structure (2LCK, Table 2) which is not
physiologically relevant [10]. Consequently, although producing IBMP
for structural studies could be considered, we have focused on targeting
heterologous membrane protein targets to bacterial membranes, ideally
in proliferating membranes.
Intracellular formation of membranes in E. coli has been observed
upon the overproduction of several classes of proteins: 1. integral
membrane proteins including the whole ATP-synthase [32] or AtpF, its
membrane bound subunit b [33], the chemotaxis receptor Tsr [34], the
sn-glycerol-3-phosphate acyltransferase [35] and the fumarate re-
ductase [36]; 2. monotopic membrane proteins including the glyco-
syltransferase MurG [37]; the monoglycosyldiacylglycerol synthase
(MGS) from Acholeplasma laidlawii [38,39] and the N-methyltransferase
PmtA from Agrobacterium tumefaciens [40]; and 3. Amphipatic protein
oligomers made of caveolin [41,42] or deriving from elastin-like pep-
tide repeats (ELP, [43]).
AtpF is a good example of an E. coli membrane protein that can be
produced either as inclusion bodies in C41(DE3) or in a folded state
within internal proliferating membranes in C43(DE3). Accumulation of
atpF mRNA is similar 3 h after induction in both expression hosts but
the time course of expression is delayed by 30min in C43(DE3) [3].
Optimized expression conditions were 16 h of induction with 0.7 mM
IPTG at 25 °C. In these conditions, the viability of the cells was restored
and overproduction of AtpF did not trigger toxicity.
Despite this example, inclusion body formation is frequent and
difficult to avoid with eukaryotic membrane protein targets. When
producing a membrane protein in bacteria, it is therefore important to
check for the presence of inclusion bodies and to prepare carefully
cellular or internal bacterial membranes. Inclusion bodies can be iso-
lated following two centrifugation steps: 600g for 10min to collect
unbroken cells and cell debris in the pellet, followed by 10,000g for
15min at 4 °C to collect inclusion bodies from the supernatant.
Bacterial membranes remain in the 10,000g supernatant; they can be
pelleted after high speed centrifugation, usually 100,000g for 1 h. To
collect bacterial membranes in the absence of inclusion bodies, disrupt
the bacteria (at least 1 L of culture) by passing the suspension twice
through a French Press or cell disruptor. If a recombinant membrane
protein triggers internal membrane proliferation, such as AtpF-induced
intracellular membranes [11], those membranes can be immediately
collected following low speed centrifugation: 2500g for 10min (P1
pellet). The pellet contains internal membranes but also unbroken cells
and debris that need to be washed away. The supernatant (S1) contains
inner and outer membranes, which are collected by centrifugation of S1
at 100,000g for 1 h at 4 °C. Proliferated membranes within P1 are then
washed and unbroken cells are removed after centrifugation at 2500g
for 10min at 4 °C. The supernatant (S2) contains the washed internal
membranes, which are collected after 1 h centrifugation at 100,000g.
The next step is to separate membrane vesicles according to their spe-
cific density on a sucrose gradient. For high purity requirements, con-
tinuous gradients are used.
4. Ptac-based protocols: The use of plasmid pTTQ18
As shown in Table 5, E. coli has been engineered and optimized for
use as an expression host to produce proteins from both prokaryotic and
eukaryotic organisms. This section is concerned exclusively with the
overexpression of genes encoding prokaryotic membrane proteins, for
which E. coli is usually an ideal expression host. The strain of E. coli
illustrated here, BL21(DE3), was selected for its lack of both the lon and
ompT proteases, and as a consequence of the previous successes
achieved for high-level expression of membrane transport proteins
[44–51]. Overexpression of all target genes is initially examined and
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plasmid pTTQ18 [45–47] containing the gene of interest, in 50ml LB
medium and inducing with 0.5mM IPTG at mid-log phase (A680 ∼
0.4–0.6). The cells are harvested 3 h after induction of the tac promoter
and total membranes are prepared from spheroplasts by the water lysis
method (Fig. 7). The total membrane proteins are separated by SDS-
PAGE and stained with Coomassie brilliant blue and/or analysed by
Western blotting with an anti-His antibody. If a protein is found to
overexpress well, scaling-up of bacterial culture volumes is undertaken
[44]. This is often performed with 30 or 100 L fermenters [52] and
inner membranes containing the protein of interest are prepared from
the cells using sucrose density gradients (Fig. 7). Note that whole cell
lysates can be used for this screening step, but there is a danger of
missing successful expression, because the protein is located only in the
membrane fraction comprising less than 10% of total cell protein, po-
tentially leading to false-negative results.
In our extensive experience of using plasmid pTTQ18 for the het-
erologous production of bacterial membrane proteins in E. coli
BL21(DE3), inclusion bodies did not appear. Rather the recombinant
protein appeared in the membrane fraction of the disrupted host cell,
where it was functionally active in all cases tested.
4.1. General choices and considerations for cloning into plasmid pTTQ18
Our preferred cloning strategy is based on the traditional restriction
enzyme method, which involves the digestion of both vector and am-
plified DNA fragments with the relevant restriction enzymes to enable
DNA ligation. This method is not high-throughput but is reliable. The
pUC-based plasmid pTTQ18 [45] is a high copy number vector, which
has been used successfully for the overexpression of diverse membrane
transport proteins of the Major Facilitator Superfamily (MFS)
Fig. 3. Tag usage for recombinant membrane protein production in microbes. Data were obtained from Tables 1–4. The number of unique membrane protein
structures is plotted as a function of the purification tag present in the corresponding recombinant membrane protein following production in (A) bacteria (black) or
(B) yeast (grey).
Fig. 4. Polyhistidine tag usage in microbial expression systems. Data were obtained from Tables 1–4. (A) The position of the polyhistidine tag within a recombinant
membrane protein and (B) the number of histidine residues it contains are shown.
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[46,47,50,53–55], the 5-Helix Inverted Repeat Transporter superfamily
(‘5-HIRT’, commonly known as the ‘LeuT’ superfamily [54,55], two-
component system (TCS) membrane regulatory proteins [56,57], Pro-
teobacterial Acinetobacter Chlorhexidine Efflux (PACE) family efflux
proteins [58] and soluble proteins (e.g. [59]). The efficacy of pTTQ18
as an expression vector for different classes of membrane proteins has
been tested and compared with other types of plasmid construct
[46,47,54,60]. Also, the desirability of placing a tag (usually (His)n) at
either the carboxyl-terminus or the amino-terminus of the cloned gene
has been discussed [61]. Plasmid pTTQ18 contains a polylinker/lacZα
region flanked by a hybrid trp-lac (tac) promoter. The tac promoter
consists of the -35 region of the trp promoter fused with the lacUV5 -10
region of the lac promoter (Fig. 8). Basal expression of the tac promoter
is minimized by binding of the LacI repressor, encoded by the lacIq
gene, to the lac operator downstream of the promoter. Also downstream
of the tac promoter is the multicloning site, which permits the use of
either EcoRI or NdeI restriction enzyme sites at the 5ˊ end of the am-
plified gene, and PstI or HindIII enzyme sites at the 3ˊ end of the gene,
for successful ligation. The pTTQ18 plasmid also contains the bla gene
for the expression of β-lactamase, conferring ampicillin or carbenicillin
resistance (Fig. 8).
The affinity tag of choice in this strategy is the RGSHis6 motif,
which is present on a modified pTTQ18 between the PstI and the HindIII
restriction sites, so incorporating the tag onto the carboxyl-terminus of
the protein (Fig. 8). The orientation of the carboxyl-terminus of the
protein is important since previous experience has shown that, if the
carboxyl-terminus is periplasmic, the use of the hexahistidine tag will
be unsuccessful (Saidijam, M., Baldwin, S.A., personal communica-
tions). A possible cause for this is the inability of the hydrophilic his-
tidine tag to traverse the hydrophobic membrane domain. It is therefore
necessary before cloning to assess the predicted topology of the protein,
Table 7
Promoter and E. coli strain combinations used for the production of re-
combinant non-E. coli (heterologous) membrane proteins.
Bacterial strain Promoter used in the expression plasmid Total





BL21(DE3) 88 7 2 3 6 1 107
BL21(DE3) ΔacrB 1 1




C43(DE3) 34 16 2 52
C43(DE3) ΔcyoABCD 1 1
C43(DE3) ΔacrB 1 1
C41(DE3) 27 2 29
C41(DE3) ΔacrB 1 1
BL21(DE3) pLysS 24 2 1 27
BL21(DE3) omp8 pLysS 1 1
BL21(DE3) CodonPlus1 14 1 1 3 19
Rosetta™ 2(DE3) T7 8 8
Rosetta™ 2(DE3) pLysS T7 5 5
BL21(DE3) Tuner 2 1 3
BL21(DE3) Star 2 2
SE1 T7 1 1
BL21(DE3) Gold 3 1 4




Origami B 1 1
Rosetta- Origami B pLysS 1 1
B834 2 1 3
B834 pLysS 1 1
PA (ΔoprH) 1 1
DH10B/TOP10 7 7
XL1-Blue 1 5 1 1 8
BL21(DE3) AI 1 1 2
DW2 1 1






M15 1 1 2











Not found 2 2
Not specified 3 1 4
Cell-free expression1 4 4
Total 229 47 15 13 24 5 3332
1 Cell-free expression of genes encoding membrane proteins using E. coli
lysates;
2 The number of expression hosts is higher than the number of uMPS because
some recombinant proteins were produced in several expression hosts.
Table 8
Promoter and E. coli strain combinations used for the production of re-
combinant E. coli (homologous) membrane proteins.
Bacterial strain Promoter used in the expression plasmid
T7 ara T5 tet trp, tac, lac, rham Native Total
BL21(DE3) 31 2 1 5 2 41
C43(DE3) 18 5 2 1 26
C41(DE3) 9 1 10
BL21(DE3) pLysS 7 7
BL21(DE3) CodonPlus 1 1
BL21(DE3) Star 1 1
BL21(DE3) Star pLysS 3 3
Rosetta™ 2(DE3) 1 1
BL21(DE3) Tuner 1 1 2
SE1 T7 1 1





















DH5α 1 1 2





JM109 1 1 2
Not specified 2 1 1 3 7
Total 80 12 9 4 16 23 144
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and investigate whether the location of the carboxyl-terminus of the
protein is expected to be cytoplasmic or periplasmic, using topology
prediction programmes such as TMHMM (www.cbs.dtu.dk/services/
TMHMM/). The location of the RGSHis6 tag on the plasmid also dictates
the use of the PstI restriction site to enable correct fusion of the protein
with the tag. However, if PstI cannot be used because of an internal PstI
site within the gene of interest, then the RGSHis6 tag can instead be
added at the primer level, and the HindIII restriction site used for re-
striction/ligation cloning.
4.2. Cloning of genes encoding membrane transport proteins
The PCR primers designed for use in many of our studies introduced
EcoRI or NdeI and PstI or HindIII restriction sites at the 5ˊ and 3ˊ ends of
the gene respectively (Fig. 8). The reaction itself was conducted using a
set of different melting/annealing/extension temperatures that varied
depending on either the melting temperature of the primers or the GC
content of the DNA to be amplified.
Following successful amplification, the resulting DNA fragment is
purified and digested with the relevant restriction enzymes. We always
designed sticky-ended ligation of the DNA fragment with pTTQ18/
RGSHis6, using the DNA ligase enzyme. The freshly-ligated DNA is used
to transform E. coli XL1-Blue cells for propagation of the plasmid and
the resulting carbenicillin-resistant colonies are selected and screened
using PCR. Size estimation of the amplified gene can be performed by
agarose gel electrophoresis and used to confirm the presence of the
Fig. 5. Promoter usage for recombinant membrane
protein production in E. coli. Data were obtained
from Tables 1–3. The graph shows the promoters
used for the heterologous (black) and homologous
(grey) production of membrane proteins in E. coli.
NS: not specified; Native: the native promoter of the
gene encoding the target membrane protein.
Table 9




BL21(DE3) E. coli str. B F– ompT gal dcm lon hsdSB(rB–mB–) λ(DE3 [lacI lacUV5 T7p07 ind1 sam7 nin5]) [malB+]K-12(λS)
C41(DE3) BL21λ(DE3) F- proY438 melB653 ycgO1103 yhhA290 ydcD71 zwf-815 rpoC3023 yehU679 rbsDΔ(IS3) λ(DE3 [lacUV5])
C43(DE3) C41λ(DE3) F- Δ(dcuS)866–870 fur::Val lonΔ(IS4) yibJ90 yjcO665 cydA::IS1 Δ(ccmF-ompC) Δ(yjiV-yjjN) rbsDΔ(IS3) λ(DE3 [lacI574
lacUV5])
BL21(DE3) pLysS BL21λ(DE3) pLysS (CamR)
BL21(DE3) CodonPlus BL21 dcm+TetR λ(DE3) endA Hte [argU proL CamR]
BL21(DE3) Star BL21 rne131 λ(DE3)
BL21(DE3) Rosetta pLysS BL21 λ(DE3) pLysSRARE (CamR)
TunerTM(DE3) BL21 lacZY1 λ(DE3)
BL21(AI) BL21 lon araB::T7RNAP-tetA
Other expression strains Genotype
BL21Rosetta BL21 RARE (CamR)
BL21-Gold BL21 dcm+TetR endA Hte
BL21-T1R fhuA2 [lon] ompT gal [dcm] ΔhsdS
Origami B BL21 lacY1 aphC gor522::Tn10 trxB (KanR TetR)
B834 F- ompT hsdSB (rB- mB-) gal dcm met
BLR F- ompT hsdSB (rB- mB-) gal dcm Δ(srl-recA)306::Tn10 (TetR)
DH10B TOP10 F- mcrA Δ(mrr-hsdRMS-mcrBC) Φ80lacZΔM15 ΔlacX74 nupG recA1 araD139 Δ(ara-leu)7697 galE15 galK16 rpsL endA1 λ- DH10B rpsL(StrR)
KRX [F′, traD36, ΔompP proA+B+ lacIq Δ(lacZ)M15] ΔompT endA1 recA1 gyrA96 (Nalr) thi-1 hsdR17 (rk– mk+) e14– (McrA–) relA1 supE44
Δ(lac-proAB) Δ(rhaBAD)::T7 RNA polymerase
XL10-Gold XL1-Blue F' [proAB lacIqZΔM15 Tn10(TetR Amy CmR)] recA1 endA1 glnV44 thi-1 gyrA96 relA1 lac Hte Δ(mcrA)183 Δ(mcrCB-hsdSMR-mrr)173 TetR
F' [proAB, lacIq ZΔM15 Tn10(TetR)] recA1 endA1 gyrA96 thi-1 relA1 supE44 hsdR17(rK- mK +) l-
DH5α F- ø80dlacZΔM15 Δ(lacZYA-argF)U169 deoR recA1 endA1 hsdR17(rK – mK+) phoA supE44 λ– thi-1 gyrA96 relA1
SG13009 NaI[s] Str[s] Rif[s] Thi[-] lac[-] Ara[+] Gal[+] Mtl[-] F[-] RecA[+] Uvr[+] Lon[+]
LS6164 ΔfadR ΔfadL
MC4100 F- [araD139]B/r Δ(argF-lac)169* &lambda- e14- flhD5301 Δ(fruK-yeiR)725 (fruA25) relA1 rpsL150(strR) rbsR22 Δ(fimB-fimE)632(::IS1)
deoC1
SCM6 NS (Patented)
MC1061 F- Δ(ara-leu)7697 [araD139]B/r Δ(codB-lacI)3 galK16 galE15 λ- e14- mcrA0 relA1 rpsL150(strR) spoT1 mcrB1 hsdR2(r- m+)
JM83 rpsL ara Δ(lac-proAB) Φ80dlacZΔM15
Other PA(ΔoprH)
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gene of interest. The resulting positive colonies are cultured and the
plasmid DNA extracted. The plasmid DNA can be subjected to double
and single restriction digestion analysis with the relevant restriction
enzymes to check that the size of the DNA insert is approximately as
expected. Integrity of the cloned gene is more certainly established by
DNA sequencing to confirm that the gene has been cloned without
mutation and is inserted into pTTQ18 with the correct orientation. The
pTTQ18 plasmid containing the sequenced gene is used to transform E.
coli BL21(DE3) cells for expression studies.
An important alternative strategy is to synthesize the gene de novo
incorporating the appropriate restriction sites for cloning, and also
modifying the codon usage of heterologous genes so they fit better to
the codon usage of E. coli.
4.3. Optimising the production of recombinant membrane transport proteins
from plasmid pTTQ18
4.3.1. Production and characterization of the protein YwtG as an exemplar
One example that we can consider in detail is the gene ywtG from
Bacillus subtilis. The translated amino acid sequence indicates YwtG is a
putative membrane transport protein, which from BLAST similarity
searches is predicted to be a MFS sugar transporter. It shares 46% se-
quence identity with a D-xylose:proton symporter from L. brevis (XylT),
39% with an arabinose:proton symporter from B. subtilis (AraE), 38%
with a major myo-inositol:proton transporter from B. subtilis (IolT) and
38% with a D-galactose:proton transporter from E. coli (GalP). Wild
type YwtG consists of 457 amino acids with a calculated Mr of
49,192.49 and is predicted by TMHMM to consist of 12 transmembrane
helices with both the amino- and carboxyl-termini located in the cy-
toplasm. YwtG contains many of the characteristic elements of the
sugar porter sub-family of the MFS including a long, central cyto-
plasmic loop, and the RGXRR sequence motif found between helices 2
and 3. As the topology of the protein allows for the addition of the
carboxyl-terminal hexahistidine tag, the recombinant YwtG protein will
contain 17 additional residues, increasing the Mr to 51,041.44.
Analysis of the ywtG gene revealed that there are no inherent EcoRI
or PstI sites within the gene enabling the use of primers designed to
introduce an EcoRI and PstI restriction site at the 5ˊ and 3ˊ ends of the
gene respectively. The ywtG gene was successfully amplified from B.
subtilis genomic DNA using an annealing temperature of 60 °C. This
fragment was digested with EcoRI and PstI, yielding a DNA fragment of
1.5 kbp (actual – 1.371 kbp; Fig. 9A). This was ligated into pTTQ18 and
used to transform E. coli XL1-Blue cells. The resulting carbenicillin re-
sistant E. coli XL1-Blue colonies were PCR screened, which revealed six
positives (Fig. 9B). These were cultured and the plasmid DNA extracted.
Double restriction digestion analysis of pTTQ18/ywtG with EcoRI and
PstI yielded two DNA fragments at 1.3 kbp and 4.6 kbp, which are si-
milar in size to the gene ywtG (1.371 kbp) and pTTQ18/RGSHis6 (4.59
kbp; Fig. 9C). DNA sequencing was performed on pTTQ18/ywtG, which
revealed that the full length ywtG gene had been cloned successfully but
one mutation was present – base number 1000 was changed from
guanine (G) to adenine (A), resulting in the YwtG(His)6 mutant D334N.
However, it is not known if this residue is important to structure or
function.
E. coli BL21(DE3) host cells harbouring the plasmid pTTQ18/ywtG
were grown in LB medium and induced with 0.5mM IPTG. Total
membranes were prepared and separated by SDS-PAGE. The Coomassie
Brilliant Blue stained gel revealed a protein band in the membranes
from the induced cells with an apparent mass of ∼31 kDa (well below
the predicted Mr) that was absent in the uninduced cell membranes,
which constituted 16% of the total membrane protein (Fig. 9D). A
positive signal was observed on the Western blot that confirmed the
identity of the YwtG(His)6 protein (Fig. 9D). A minor signal was also
observed in the uninduced cells, which is possibly due to ‘leaky’ dere-
pression of the tac promoter on pTTQ18.
4.3.2. Anomalous migration of recombinant YwtG and other membrane
transport proteins in SDS-PAGE gels
The relative molecular masses of protein bands observed in
Coomassie-stained SDS-PAGE gels and Western blotting film were de-
termined by comparing their migrating distances with those of standard
protein molecular weight markers. There is a linear relationship be-
tween the log10Mr of YwtG, BC0935, BC5418 and YhjI and the distance
they migrate on the SDS-PAGE gel.
For many membrane proteins, and especially membrane transport
proteins, boiling to solubilize in SDS before running the gel leads to
irreversible aggregation and insolubility. Instead we routinely
Table 10
Promoter and yeast strain combinations used for the production of homologous
and heterologous recombinant membrane proteins.

















W303 pep4Δ 1 1 2
WB12 1 1
Not stated 1 1 2






Not stated 1 1 2
Total 30 1 31
Table 11
Genotypes of yeast strains used to produce recombinant membrane proteins for
structural determination.
S. cerevisiae Genotype
ADΔ MATα PDR1-3 Δyor1::hisG Δsnq2::hisG Δpdr3::hisG Δpdr10::hisG
Δpdr11::hisG Δycf1::hisG Δpdr5::hisG Δpdr15::hisG Δura3
ΔhisAD124567 Δpdr5::hisG Δpdr15::hisG, Δura3
BJ1991 MATα pep4-3 prbl-1122 ura3-52 leu2 trpl
BJ2168 MATa leu2 trp1 ura3-52 prb1-1122 pep4-3 prc1-407 gal2
BJ5457 MATα pep4::HIS3 prb1-Δ trp1 ura3-52 leu2-Δ his3-Δ lys2-801
can1
BJ5460 MATa ura3‐52 trp1 lys2‐801 leu2Δ1 his 3Δ200 pep4::HIS3
prb1Δ16
CACY1
DSY-5 MATa leu2 trp1 ura3-52 his3 pep4 prb1
FGY217 MATa ura3-52 lys2Δ201 pep4Δ
INVSc1 MATa his3Δ1 leu2 trp1-289 ura3-52
JTY002
W303 pep4Δ MATa leu2-3112 trp1-1 can1-100 ura3-1 ade2-1 his3-11,15
pep4Δ




KM71 his4 arg4 aox1::ARG4/MutS His−
SMD1163 his4 Δpep4 Δprb1/Mut+ His−
X33 wild-type/Mut+
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solubilize the protein in SDS at temperatures of 30–60 °C for 10–60min.
Such solubilized samples may contain partially-unfolded protein and/or
sub-optimal SDS:protein ratios that lead to anomalous migration in the
gel. Generally the observed molecular weight is less than predicted
(Table 13), though there are often higher molecular weight bands that
may represent completely unfolded protein, oligomers, or aggregates.
In our experience, the anomalous lower molecular weight bands, as
well as the higher ones, are an idiosyncrasy of SDS-protein behaviour –
see e.g. [50,53,55–58] and their presence does not imply anything is
wrong with the protein.
4.3.3. Dependence of recombinant protein yields on growth and induction
conditions
The extent of growth before and after induction can vary, meaning
that it is advisable to conduct trials that aim to maximize the amount of
cells without compromising the level of the desired recombinant
protein in the membrane. Usually, recombinant protein yields in
amounts greater than 2–5% of the total inner membrane protein com-
position trigger cell toxicity, compromise growth and reduce the bio-
mass yield of cells and membranes, whereas it is necessary to achieve
levels of 10–50% in order to facilitate later purification and the mini-
mization of contaminating proteins. Generally, 10% is regarded as sa-
tisfactory, 20–30% is desirable and often achieved, and 50% was
achieved in only one case out of over 100 recombinant proteins pro-
duced. These higher levels seriously compromise cell growth and net
production. Thus, a compromise needs to be arrived at where induction
is left late to maximize the yield of cells, but not so late that the level of
induction is reduced.
For each protein that is taken forward for characterization and
purification, we try first to determine whether expression is best in rich
or minimal medium. We then try a dose–response curve measuring the
level of expression achieved in membranes exposed to zero and
Fig. 6. Selection of bacterial strains for improved
recombinant membrane protein production using
GFP as a gene reporter. Isolation of bacterial mutant
hosts was performed as described in Section 3.2 of
this review and previously [30]. Briefly, the pMW7-
GFP-Xa expression plasmid was transformed into
BL21(DE3) cells and a single colony was inoculated
in 50ml 2*TY medium. At A600=0.4, cells were
diluted in water and 100 μl of the 10−1 dilution were
plated on an IPTG-containing plate. Plates were il-
luminated under (A) normal light (two small colonies
that did not emit fluorescence are encircled) or (B)
UV light (arrows indicate four large colonies that
emitted a diffuse fluorescence). Panels (C) and (D)
show two other independent experiments with petri
dishes illuminated under UV light.
Table 12
Optimization of growth conditions in the IPTG-inducible T7RNAP expression system.
Size of colonies on IPTG plate1 Inoculation Induction IPTG concentration Temperature after induction
No colony no preculture2 No induction3 None 30 °C or below
A600=1 10 μM
4, 0.1 μM
Small (>10% reduction) preculture5 A600<0.6 0.4 or 0.7mM 37 °C or 25 °C
Minor reduction (<10%) preculture A600<0.4 0.7mM 37 °C or 25 °C
1 Try 0.7mM and 0.4mM of IPTG and check the phenotype on plates at 37 °C and room temperature.
2 If you need a preculture to grow large volumes or to inoculate a fermenter, then check plasmid stability.
3 See [27,28].
4 See [29] for a complete description of the procedure.
5 Pre-warm the medium and use the pre-culture at 10−2 dilution; when the plasmid is stable, antibiotic is no longer required in the large-scale culture.
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increments within 0.01–2mM IPTG. In some cases we have also ex-
plored ‘autoinduction’ using lactose/glucose mixtures [44]. This econ-
omises on expensive IPTG, but can take some time before achieving
good results. An optimal situation is arrived at where larger scale
(30–100 L) cell growth is conducted in fermenters [52] and extended to
A680=0.6–1.0, when inducer is added for 1–3 h before harvesting,
cooling and freezing the concentrated cell suspension at −80 °C for
storage. In the great majority of expression studies using constructs in
the pTTQ18 plasmid we have simply used a growth temperature of
37 °C and maintained it during induction, but there are indications that
lowering the temperature at the time of induction is beneficial.
Provided the concentrated cells are kept frozen at −80 °C, the re-
combinant proteins in the inner membrane that we have studied appear
to be immortal. Aliquots of cells can be thawed, membranes prepared
and the proteins purified any time later (yes, years), though their sta-
bility is not necessarily guaranteed during and after purification, of
course.
5. Yeast expression systems for membrane protein production
Yeast is both microbial and eukaryotic, meaning it is quick, cheap
and easy to culture, whilst having the post-translational pathways
present in higher eukaryotic host cells that are absent in bacteria [62].
The two yeast species most widely used for recombinant membrane
protein production are S. cerevisiae and P. pastoris [63,64] (Table 5).
Both grow quickly in a range of complex and defined media (doubling
times are typically 2.5 h when glucose is the carbon source) in vessels
ranging from multi-well plates to shake flasks and bioreactors [64].
P. pastoris is notable for being able to grow to very high cell den-
sities under controlled conditions where oxygenation rates are high
(>100 g/L dry cell weight; >500 A600 units/mL [19]) and therefore
has the potential to produce large amounts of recombinant membrane
protein for structural analysis. High-resolution crystal structures of the
adenosine A2A [65] and the histamine H1 [66] GPCRs have been solved
using recombinant protein derived from P. pastoris. More recently, a
2.9 Å resolution crystal structure was published of the first plant mul-
tidrug and toxic compound extrusion (MATE) transporter to be struc-
turally characterized; the crystals were formed using recombinant
protein synthesized in P. pastoris [67].
S. cerevisiae is notable for being supported by a more extensive lit-
erature than P. pastoris. Its genetics are also better understood (http://
www.yeastgenome.org/). This means that there is a much wider range
of tools and strains for improved membrane protein production in this
yeast. Recent examples of its use include the generation of the 4.4 Å
cryo-EM structure of the rat TRPV2 channel [68] and the 3.0 Å crystal
structure of the wild-type human GLUT1 glucose transporter in complex
with cytochalasin [69].
The experimental strategy for obtaining the structure of the hista-
mine H1 receptor provides an example of making best use of the two
yeast species’ strengths: crystals were obtained from protein produced
in P. pastoris, while initial screening to define the best expression con-
struct was performed in S. cerevisiae [70]. In principle, many of the tools
established for S. cerevisiae could be transferred to P. pastoris (for which
a genome sequence was published in 2009 [71]) combining the
strengths of both yeast species, although such work would be time-
consuming. In our laboratory, we often start with P. pastoris and, if the
production is not straightforward, use S. cerevisiae to troubleshoot [64].
In the following sections, we include the production of the human
GPCR, adenosine A2A receptor (hA2AR), in both species as an exemplar
(Figs. 10 and 11).
5.1. Saccharomyces cerevisiae
In studies examining the host response to recombinant membrane
protein production, the unfolded protein response [72] and altered ri-
bosomal biogenesis [73] have been identified as major determinants of
high yields in yeast, although the precise mechanistic reasons for this
remain unclear.
Fig. 7. Preparation of membranes from E. coli cultures. Schemes for the (A) small-scale preparation of mixed inner and outer membranes or (B) large-scale pre-
paration of separated inner or outer membranes from cultures of E. coli.
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5.1.1. Selection of yeast expression strains for improved membrane protein
production
A comprehensive strain collection exists from which potential ex-
pression hosts can be selected, supported by information in the
Saccharomyces Genome Database (http://www.yeastgenome.org/). The
yeast deletion collections comprise over 21,000 mutant strains with
precise start-to-stop deletions of approximately 6000 S. cerevisiae ORFs
[74]. The collections include heterozygous and homozygous diploids as
well as haploids of both MATa and MATα mating types. Individual
strains or the complete collection can be obtained from Euroscarf
(http://web.uni-frankfurt.de/fb15/mikro/euroscarf/) or the American
Type Culture Collection (http://www.atcc.org/). Dharmacon sells the
Yeast Tet-Promoters Hughes Collection (yTHC) with 800 essential yeast
genes under control of a tetracycline-regulated promoter that permits
experimental regulation of essential genes. A number of specifically-
engineered S. cerevisiae strains also exists including those with ‘huma-
nized’ sterol and glycosylation pathways [75]. Protease-deficient strains
are a consistently-popular choice in membrane protein structural
biology projects (Table 10 and 11). Often, the standard BY4741 la-
boratory strain (MATα, ura3Δ0, leu2Δ0, met15Δ0, his3Δ1) is a good
start, but it is not always the most successful, as shown for the ex-
pression of hA2AR (Fig. 10A).
We previously selected four strains of S. cerevisiae for their ability to
produce the aquaporin Fps1 in sufficient yield for further study [73].
Yields from the yeast strains spt3Δ, srb5Δ, gcn5Δ and yTHCBMS1
(supplemented with 0.5 μg/mL doxycycline) that had been transformed
with an expression plasmid containing 249 base pairs of 5ˊ untranslated
region (UTR) in addition to the primary FPS1 open reading frame (ORF)
were 10–80 times higher than yields from wild-type cells expressing the
same plasmid. One of the strains increased recombinant yields of hA2AR
and soluble green fluorescent protein (GFP); all but gcn5Δ were found to
exhibit a block in translation initiation. Expression of the eukaryotic
transcriptional activator GCN4 was increased in these strains and they
also exhibited constitutive phosphorylation of the eukaryotic initiation
factor, eIF2α. Both responses are indicative of a constitutively-stressed
phenotype.
Investigation of the 5ˊUTR of FPS1 in the expression construct re-
vealed two untranslated ORFs (uORF1 and uORF2) upstream of the
primary ORF. Deletion of either uORF1 or uORF1 and uORF2 further
improved recombinant yields in our four strains; the highest yields of
the uORF deletions were obtained from wild-type cells. Frame-shifting
the stop codon of the native uORF (uORF2) so that it extended into the
FPS1 ORF did not substantially alter Fps1 yields in spt3Δ or wild-type
cells, suggesting that high-yielding strains are able to bypass 5ˊuORFs in
the FPS1 gene via leaky scanning, which is a known stress-response
mechanism. Yields of recombinant hA2AR, GFP and horseradish per-
oxidase could be improved in one or more of the yeast strains sug-
gesting that a stressed phenotype may also be important in high-
yielding cell factories [76].
From these studies we concluded that regulation of Fps1 levels in
yeast by translational control might be functionally important and the
presence of a native uORF (uORF2) may be required to maintain low
levels of Fps1 under normal conditions, but higher levels as part of a
stress response. We also concluded that constitutively-stressed yeast
strains may be useful high-yielding microbial cell factories for re-
combinant membrane protein production [76].
5.1.2. Using selective advantage to improve membrane protein yields in S.
cerevisiae
Making the production of a target recombinant protein a condition
for yeast cell survival should give producers a selective advantage over
non-producers. This principle has been examined previously for the
production of membrane proteins in prokaryotic hosts [77–79]. How-
ever, functional yields were not assessed; instead total yields were
quantified by immunoblot [77–79]. We therefore investigated whether
yeast cells could be given a selective advantage to produce high yields
of hA2AR by fusing it with the orotidine-5-monophosphate decarbox-
ylase polypeptide (Ura3p). Ura3p catalyzes the sixth step in the de novo
biosynthesis of uridine monophosphate in yeast and is required by ura3
deletion strains when they are cultured in uracil-deficient growth
medium [80].
Transformation of S. cerevisiae strain BY4741 (MATα, ura3Δ0,
leu2Δ0, met15Δ0, his3Δ1) with a control plasmid (pYX222-hA2AR)
generated colonies on solid histidine-deficient growth medium that
were designated A2 (the control, producing hA2AR). BY4741 transfor-
mants expressing hA2AR-Ura3p (following transformation with
pYX222-hA2AR-URA3) were selected using either a 1- or 2-step process.
In the 1-step process, yeast cells were grown on solid uracil-deficient
medium immediately following transformation; this generated a single
colony designated A2U1 (A2SU1 was similarly generated following
transformation of the yeast deletion mutant strain, spt3Δ). In the 2-step
process, yeast cells were cultured on solid histidine-deficient medium
following transformation and colonies were spotted onto solid uracil-
deficient medium (generating A2H1; Table 14 and Fig. 10).
The total yield of hA2AR-Ura3p fusion proteins was analysed by
immunoblot following transformation and selection on nutrient-defi-
cient medium. Table 14 shows that the yield of hA2AR-Ura3p from
A2H1 was almost 7-fold higher than the yield of hA2AR from the A2
control. No hA2AR-Ura3p was detected from the A2U1 transformant.
The yield of hA2AR-Ura3p from A2SU1 was just over half that of A2,
with spt3Δ:hA2AR, showing no signal. Changes in the expression levels
could also be determined using immunofluorescence staining (Fig. 10)
where increased levels of the newly-synthesized A2 receptors could be
seen along with the Ura3p-fusions in A2H1 and A2SU1 (Fig. 10). This
suggests that making the production of a recombinant GPCR a condition
for cell survival through nutrient selection is an effective method to
increase total yield. To determine whether the hA2AR-Ura3p we had
produced was correctly folded and thereby estimate the functional yield
of the hA2AR moiety, a radio-ligand binding assay was performed [81].
Radio-ligand binding analysis was done using the well-characterized
antagonist [3H]ZM241385 [82] on 100 µg of total membrane extract
from A2, A2H1 and A2U1. Table 14 shows that A2H1 produced only a
minimal increase (1.6± 0.1 pmol mg−1) of correctly-folded hA2AR-
Ura3p compared to the A2 control (1.1± 0.1 pmol mg−1). The yield of
hA2AR-Ura3p from A2U1 was negligible (0.2± 0.01 pmol mg
−1). These
findings suggested that the protein produced using this strategy was a
heterologous mixture of correctly folded (binding-competent) and
misfolded (binding incompetent) protein. In contrast the functional
yield of hA2AR-Ura3p from A2SU1 was increased almost 3-fold
(3.0± 0.2 pmol mg−1) over the A2 control and 6-fold over the mutant
strain control spt3Δ:hA2AR (Table 14). Notably, ligand binding activity
could be recovered from A2H1, but not A2 or A2SU1, by solubilising
the hA2AR-Ura3p in n-dodecyl β-D-maltopyranoside (DDM; Table 14).
We validated single-point binding with full saturation curves for A2,
A2H1 and A2SU1 in membranes. The Bmax values from these experi-
ments validate the single-point saturation values. Affinity was de-
termined using competition binding experiments, with the pKd being
8.3–8.6 for A2, A2H1 and A2SU1.
In order to rationalize why the functional yield was lower than the
total yield, we examined the localization of hA2AR-Ura3p using con-
focal microscopy following staining of yeast spheroplasts with a mouse
anti-hexahistidine antibody followed by an Alexa488-conjugated goat-
anti-mouse antibody. Fig. 10A shows confocal images for BY4741 ex-
pressing no recombinant protein (panel i), the control plasmid pYX222-
A2AR (panel ii) and A2H1 (panel iii); in the latter image, a vacuolar
localization of the recombinant protein is observed. Fig. 10A, panel iv
shows that vacuolar accumulation of the hA2AR -Ura3p fusion could be
reduced by using the BY4741 spt3Δ strain. Homologous competition
radio-ligand binding with [3H]ZM241385 (Fig. 10B) demonstrated that
hA2AR and hA2AR-Ura3p had comparable pKd values (8.3–8.6) as re-
ported in the literature [83].
When nutrient selection was used as a strategy to increase the yield
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of another recombinant GPCR, the human β2 adrenergic receptor
(hβ2AR), high yielding transformants were found to have been gener-
ated using the 2-step method. B2U1 and B2U5 gave a 3.2- and 2.5-fold
increase in total yield and a 5- and 7-fold increase in functional yield
(when solubilized with DDM) of hβ2AR-Ura3p, respectively, compared
to the B2 control. The 1-step method (leading to transformant B2H3)
did not result in an increased functional yield following DDM-solubi-
lization. However solubilization using 2.5% styrene maleic acid co-
polymer (SMA; 2:1 styrene to maleic acid ratio), increased the func-
tional yield of the control B2 and B2H3 compared to DDM solubiliza-
tion.
The constructs used in these experiments were not truncated ther-
mostable constructs that had been optimized for recombinant expres-
sion. Rather, they were the full wild-type sequences (that had been
codon optimized for yeast). The data in Table 14 suggest that prior to
solubilization, either the receptor was not correctly-folded in yeast
membranes or that it was expressed below the limit of detection when
we assayed 100 µg membranes. Extraction by surfactant and subsequent
concentration resulted in function being detected suggesting that this
process had recovered correctly-folded recombinant protein. This ap-
proach demonstrates the power of applying a selective advantage
strategy to recombinant GPCR production and provides insight into the
role of targeting and quality control.
5.2. Pichia pastoris
One notable and highly-beneficial feature of producing recombinant
membrane proteins in P. pastoris (and that has been reviewed
extensively elsewhere) is that exceptionally high yields of correctly-
folded protein can be obtained, especially under the tightly-controlled
conditions achieved in bioreactor cultures. For example, yields of both
human aquaporin 1 (hAQP1) and hA2AR in bioreactors were more than
double those achieved in equivalent shake flask cultures [19]. More-
over, the bioreactors produced higher quality membrane protein as
determined by functional assay (more than 150 pmol/mg is reported in
several studies [84]). Isolation of hAQP1 was possible at 90mg/L, while
yields of 13mg/100 g cells were reported for a codon-optimized P-
glycoprotein construct [19]. P. pastoris is therefore a highly attractive
system for the production of folded, eukaryotic membrane proteins
although yields remain protein dependent.
P. pastoris expression plasmids are usually integrated into the yeast
genome to produce a stable production strain. Since it is not possible to
control precisely the number of copies that integrate, or indeed where
they integrate within the genome, the optimal clone must be selected
experimentally [85]. One approach is to screen on increasing con-
centrations of antibiotic (usually zeocin) to obtain so-called ‘jackpot’
clones. However, the correlation between the copy number of the in-
tegrated expression cassette (as determined by resistance to increasing
zeocin concentrations) and the final yield of recombinant protein is not
always positive [16]. Sometimes clones with lower copy numbers are
more productive, suggesting that the cellular machinery is over-
whelmed in jackpot clones (resulting in misfolded or degraded protein).
Consistent with this idea, hA2AR yields were increased 1.8-fold when
the corresponding gene was co-expressed in P. pastoris with the stress-
response gene HAC1 [86]; Hac1 drives transcription of UPR genes.
In contrast to the situation in S. cerevisiae, far fewer P. pastoris
Fig. 8. Strategy for cloning and expressing genes of bacterial membrane proteins using plasmid pTTQ18-His6. Each target gene was inserted into the multiple cloning
site (MCS) downstream of the tac promoter in the plasmid pTTQ18-His6 in order to amplify gene expression. Two different restriction enzymes, EcoRI and PstI were
used to ensure correct orientation of the gene on ligation into plasmid pTTQ18-His6, as well as to prevent re-ligation of the plasmid. First, the membrane protein gene
was amplified by PCR using bacterial genomic DNA as template and introducing EcoRI at the 5ˊ-end and PstI at the 3ˊ-end, followed by digestion with these two
enzymes and ligation with EcoRI-PstI – digested pTTQ18-His6. The resulting plasmid construct with the gene inserted was then transformed into E. coli XL10-Gold
cells, followed by colony PCR to identify positive clones. The sequence encoding the hexahistidine tag (yellow) is incorporated into the pTTQ18 plasmid so it is in
frame with the ligated gene. This works well when the carboxyl terminus of the recombinant protein is finally located inside the cell membrane. However, if the
carboxyl terminus is destined to be outside the cell membrane, translocation of the fused positively-charged histidines appears to compromise expression. In this
latter case, fusion a Strep II tag (red) can be used instead. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version
of this article.)
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strains are available in which to integrate the expression plasmid for the
generation of a recombinant production strain (Table 10 and 11). The
wild-type strain, X33, the histidine auxotroph GS115, and the slow-
methanol-utilization strain KM71H, have all been used to produce
membrane proteins for structural studies [19]. Protease-deficient
strains such as SMD1163, which lacks proteinase A and proteinase B,
are also available (Table 10 and 11).
In all these strains, P. pastoris (like S. cerevisiae) post-translationally
glycosylates membrane proteins by adding core (Man)8-
(GlcNAc)2 groups, but not the higher-order structures found in humans
and other mammals; compared to S. cerevisiae, the mannose chains also
tend to be shorter. However, the effects of these non-native modifica-
tions are not necessarily detrimental and need to be assessed on a case-
by-case basis [84]. The high-resolution structure of a glycosylated form
of the Caenorhabditis elegans P-glycoprotein (using recombinant protein
produced in P. pastoris) demonstrates that yeast glycosylation does not
necessarily hinder crystal formation [87]. Nonetheless, in order to
overcome potential bottlenecks in producing, purifying, characterizing
and crystallizing human proteins in yeast, engineered strains have been
developed including strains with ‘humanized’ glycosylation [88,89] and
sterol pathways.
Most proteins produced in P. pastoris for structural biology use
variations of the standard methanol induction protocol. Fig. 11 shows
an example of the recombinant production and purification of hA2AR
following the ‘Pichia Fermentation Process Guidelines’ (Invitrogen).
The hA2AR protein in this study was tagged with an amino-terminal
decahistidine-tag and incorporated an N154Q mutation to prevent
glycosylation (the corresponding gene was expressed from the pPICZαA
expression plasmid). Cells were cultured in a bioreactor and depletion
of glycerol in the initial glycerol batch phase was indicated by a spike in
the dissolved oxygen (DO) reading. This was followed by a fed-batch
phase with a 50% (w/v) glycerol solution and a 3 h starvation phase to
achieve complete glycerol consumption. During the final hour of star-
vation, the temperature was reduced from 30 °C to 22 °C and allowed to
stabilize. Theophylline, a non-selective hA2AR antagonist (10mM) was
then added to the culture to increase stabilization during expression.
Fig. 9. Production of the YwtGHis6 protein from B. subtilis in E. coli. (A) Amplification and digestion of the ywtG gene. (B) PCR screening of carbenicillin-resistant E.
coli XL1-Blue colonies. (C) Identification of the ywtG gene using double restriction digestion of pTTQ18/ywtG with EcoRI and PstI. (D) Coomassie Brilliant Blue
stained gel (left panel) of membrane preparations made from induced and uninduced cells (as indicated) and Western blot analysis (right panel) of the overexpressed
YwtGHis6 protein. There is some expression in the uninduced cells, indicative of ‘leaky’ expression. (For interpretation of the references to colour in this figure
legend, the reader is referred to the web version of this article.)
Table 13
Predicted and calculated sizes of membrane proteins. Protein sizes were calculated from both Coomassie-stained and immunoblotted SDS-PAGE gels. YwtG from
Bacillus subtilis is predicted to be a sugar transport protein, BC0935 from Bacillus cereus a dicarboxylate/α-ketoglutarate transporter, BC5418 from B. cereus a sugar/
metabolite transporter and Yhj1 from B. subtilis a glucose transporter. The data for YwtG are from a different experiment from that shown in Fig. 9, explaining the
minor discrepancies in apparent molecular masses.
Protein Predicted molecular mass
(kDa)
Determined by Coomassie-stained SDS-PAGE Determined by Western blot detecting the His6 tag Ratio of observed size/actual
size
Migrated distance (cm) Calculated size (kDa) Migrated distance (cm) Calculated size (kDa)
YwtG 51,042 5.5 40 4.3 41 0.78
BC0935 49,906 6.2 34 4.75 35 0.68
BC5418 45,541 6.6 31 5.0 31 0.68
YhjI 49,477 6.5 32 4.85 35 0.65
M.V. Dilworth et al. Methods xxx (xxxx) xxx–xxx
32
The cells were induced with 100% methanol at an initial feed rate of
1.92ml/h for 17 h to allow adaptation to methanol. When a steady DO
rate and fast DO spike time were obtained, the feed rate was increased
to 3.96ml/h for the remainder of the culture duration. The entire
methanol fed-batch phase lasted approximately 40 h with a total of
∼125ml of methanol fed per litre of initial volume. The cells were then
harvested by centrifugation.
In a study of the regulation of carbon substrate utilization, we cul-
tured wild-type P. pastoris cells in methanol and found that a higher
proportion of the total mRNA pool was associated with two or more
ribosomes (and therefore judged to be highly translated) compared to
the same cells cultured in any other non-inducing growth condition
Fig. 10. Localization and pharmacological
analysis of recombinant hA2AR/hA2AR-
Ura3p expression in S. cerevisiae. (A)
Confocal microscopy visualization of (i)
control BY4241 cells, (ii) recombinant
hA2AR produced from transformant A2, (iii)
recombinant hA2AR-Ura3p expressed after a
1-step selection from transformant A2H2
and (iv) recombinant hA2AR-Ura3p ex-
pressed after a 2-step selection from trans-
formant A2SU1. Cells were grown to
A600=4–5 and were visualized using rabbit
anti-His6 (Clontech) as the primary antibody
and an Alexa-Fluor488-conjugated anti-
rabbit secondary antibody. (B) Homologous
competition binding experiments were per-
formed for hA2AR/hA2AR-Ura3p produced
from A2, A2H2 and A2SU1 using labelled
([3H]) and unlabelled ZM241385.
Experiments were done on 100 µg total
membrane protein, with A2 acting as the
control. Error bars represent the standard
deviation (n= 3).
Table 14
Characterization of recombinant hA2AR/hA2AR-Ura3p- and β2AR/β2AR-Ura3p-producing transformants. Confocal microscopy visualization of recombinant hA2AR/
hA2AR-Ura3p in transformed S. cerevisiae using AlexFluor488 antibodies was done to assess whether hA2AR/hA2AR-Ura3p was localized in the membrane or had been
internalized to the vacuole. Immunoblots (50 µg total membrane protein loaded per well, as determined by BCA assay, and probed with Clontech anti-His6 antibody)
were quantified using ImageJ. This allowed comparison of recombinant protein yield from A2H1, A2U1 and A2SU1 (BY4741 or spt3Δ were transformed with
pYX222-hA2AR-URA3 and grown under conditions of nutrient selection) compared with the A2 control (BY4741 transformed with pYX222-hA2AR) or spt3Δ:hA2AR
(spt3Δ transformed with pYX222-hA2AR). For hβ2AR, B2H3, B2U1 and B2U5 were compared with the B2 control. The functional yield for hA2AR/hA2AR-Ura3p or
β2AR/β2AR-Ura3p in yeast cell membranes or following solubilization with 2.5% DDM, 0.5% CHS was determined by single-point saturation binding using the
antagonists [3H]ZM241385 or [3H]CGP 12 177, respectively and 100 µg total membrane protein per experiment, as described in [73]. A 1-way ANOVA with a Holm-
Sidak’s multiple comparison test gave p= 0.001 (***) for A2H1 (without DDM treatment) versus A2H1(solubilized with DDM). Additionally, β2AR/β2AR-Ura3p was
solubilized using 2.5% (w/v) styrene maleic acid (SMA) polymer with a 2:1 ratio of styrene to maleic acid. All data are derived from at least 3 independent biological







Total yield from immunoblot
(Arbitrary units; relative to control)
Functional yield
(pmol mg−1)
Functional yield following DDM
solubilization (pmol mg−1)
Functional yield following SMA
solubilization (pmol mg−1)
hA2AR
A2 (control) BY4741 No 1.0 1.1 (0.2) 1.2 (0.3) n/a
A2H1 BY4741 Yes 6.8 (0.8) 1.6 (0.1) 5.8 (1.6) n/a
A2U1 BY4741 n/a 0.0 0.2 (0.01) n/a n/a
A2SU1 spt3Δ No 0.6 (0.2) 3.0 (0.2) 3.2 (0.7) n/a
spt3Δ:hA2AR spt3Δ No n/a 0.5 (0.1) n/a n/a
β2AR
B2 (control) BY4741 n/a 1.0 0.0 0.3 (0.02) 1.26 (0.2)
B2H3 BY4741 n/a 2.4 (1.5) 0.0 0.3 (0.1) 0.93 (0.3)
B2U1 BY4741 n/a 3.2 (0.3) 0.0 1.6 (0.3) 1.43 (0.4)
B2U5 BY4741 n/a 2.5 (0.2) 0.0 2.2 (1.0) 1.12 (0.6)
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[90]. This observation suggests that high recombinant protein yields in
methanol-grown cells are due not just to promoter strength, but also to
the global response of P. pastoris to growth on methanol [90]. We have
also demonstrated pre-induction expression under the control of PAOX1
[91], suggesting that the uncoupling of growth and protein synthesis in
P. pastoris cells has not yet been achieved and may provide opportu-
nities for future optimization studies.
6. An overview of detergent usage for microbially-produced
recombinant membrane proteins
For membrane protein investigations, the choice of the detergent is
crucial, as a suitable one is needed to prepare a pure, stable and mono-
dispersed protein in solution but also to grow well-ordered crystals
without preventing crystal contacts. As a consequence, the best de-
tergent for solubilization is often not the best for crystallization and a
detergent exchange procedure during purification is a common ap-
proach (Tables 1–4). Notably, more than 50% of the membrane proteins
in the PDB have been crystallized in a detergent or a detergent mixture
that is different from the detergent used for membrane protein solubi-
lization (Fig. 12).
Folded membrane proteins in their native membranes can usually
be solubilized with detergent. However after production in hetero-
logous membranes, it is frequently found that recombinant membrane
proteins are difficult to solubilize. Our simple solubilization screen
compares the solubility of the target membrane protein at 1mg/mL in
three different detergents ten times above their critical micellar con-
centration (cmc): DDM (1% final concentration), FC12 (1%) and SDS
(2%). After 1 h incubation at 4 °C on a stirring wheel, insoluble material
is removed by ultracentrifugation at 100,000g for 30min. The pellet is
resuspended with TEP buffer (0.25mM EDTA, 0.1 mM phe-
nylmethylsulfonyl fluoride and 10mM Tris-Cl pH 7.8; same volume as
that of the supernatant) and both solubilized and non-solubilized
fractions are loaded onto an SDS-PAGE gel. If the target membrane
protein is solubilized only by SDS, it is likely to be in inclusion bodies
(these structures are most frequently associated with bacterial expres-
sion systems). If it is solubilized by all three detergents, then it is likely
to be well-folded. If DDM cannot solubilize the target membrane pro-
tein, experience tells us that it is likely to be misfolded. However, there
are many combinations of detergent that can be used to potentially
overcome this problem.
The data presented in Fig. 12 show significant differences between
detergents used in solubilization and crystallization of β-barrel
(Fig. 12A, Supplementary Table 1) and α-helical (Fig. 12B–D,
Supplementary Table 1) membrane proteins. For monotopic and α-he-
lical membrane proteins, the most common detergents used for solu-
bilization are by far the maltosides (78%, 72% and 59% for E. coli, S.
cerevisiae and P. pastoris expression systems, respectively) and with
DDM contributing more than 80% to this detergent family. DDM is a
mild, low cmc, long alkyl chain detergent and has been found to be very
stabilising explaining its success in maintaining dynamic membrane
proteins in solution. However its large micelles are not well adapted to
form ordered, well-diffracting crystals because they limit essential
crystal contacts. Therefore, while maltosides are the major detergents
used for crystallization of α-helical membrane proteins produced in E.
coli (48%), an important contribution is made by the smaller glucosides
(15%) and especially OG, followed by detergent mixtures (15%) and
Cymal detergents (6%). For membrane proteins produced in S. cerevi-
siae and P. pastoris, the profile of detergent usage is similar with the
exception of neopentylglycol detergents that are used more often (7%
and 14%, respectively).
Glucosides (OG, NG) have a high cmc and form small micelles al-
lowing better packing in crystal lattices and resulting in better dif-
fracting crystals [92,93]. OG in particular has been used successfully for
channel proteins [92] such as the five OG-crystallized aquaporins de-
rived from P. pastoris. The success of detergent mixtures also suggests
that combinations of detergents (mostly with small micelle-sized de-
tergents) have a useful contribution to make.
For β-barrels, the three most successful detergents for solubilization
are detergent mixtures (24%), the zwitterionic amine oxide detergents
(17%) and the maltosides DDM/DM (12%). Strikingly, C8E4, C10E5 or
C10E6 are the best detergents for crystallization accounting for half of
the structures (42%) followed by detergent mixtures (18%), and amine
oxide detergents (16%), in agreement with an earlier study [94]. The
high stability of the β-barrel fold supports the use of smaller-micelle-
size detergents and more destabilizing detergents.
7. Conclusions
Microbes have an important role to play in membrane protein
structural biology projects. E. coli, P. pastoris and S. cerevisiae have to-
gether been used to produce 71% of all unique structures in the PDB that
Fig. 11. Purification of the human adenosine A2A receptor in P. pastoris under the control of PAOX1. (A) Human A2AR eluted from Ni
2+
–NTA linked agarose as a single
band in Coomassie-stained fractions with 250mM imidazole. (B) Silver-stained band of the 250mM imidazole fraction with an anti-histidine antibody.
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were derived from recombinant sources. In this review we have focused
on an analysis of the host strains, tags and promoters that, in our ex-
perience, are most likely to yield protein suitable for structural and
functional characterization. We have also exemplified some of our
preferred protocols. There are, of course, may other factors that could
be considered including codon optimization, mutagenesis, the use of
other microbes, engineering of the membrane lipid composition and an
in-depth analysis of the culture medium composition. We note, how-
ever, that in many cases the approaches we have catalogued provide the
requisite quantity and quality of protein for further study.
One of the major challenges in the forthcoming years will be to
overcome the barrier of producing complex eukaryotic membrane
proteins in microbial systems. There are numerous reports of misfolded
recombinant proteins being produced in human cells and tuning human
promoters to favour efficient folding is still in its infancy. In contrast
there are several initiatives to ‘humanize’ microorganisms. For instance
S. cerevisiae has been engineered to synthetize cholesterol instead of
ergosterol in order to favour the activity of human GPCRs in yeast
membranes. Some T7RNAP-based E. coli strains are fully devoid of li-
popolysaccharides and are now recognized as being as safe as
Lactobacillus. Finally, the genetic diversity of microorganisms is now a
source of inspiration. For instance some groups are developing semi-
synthetic hosts based on magnetotactic bacteria that contain sophisti-
cated intracellular organelles [95]. We therefore anticipate that mi-
crobes will continue to make important contributions to the production
of recombinant membrane proteins from a range of prokaryotic and
eukaryotic organisms.
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Fig. 12. Detergent usage for the solubilization and crystallization of membrane proteins. Data were obtained from Tables 1–4. Detergent usage for the solubilization
(grey) and crystallization (black) of (A) β-barrel membrane proteins produced in E. coli and of α-helical membrane proteins produced in (B) E. coli, (C) S. cerevisiae or
(D) P. pastoris. Detergents are classified as follows: Maltosides (DDM, UDM, Tri-DM, DM, NM, OM and TDM); Glucosides (OG, OTG, NG, C7G); Poly-
oxyethyleneglycols (C12E9, C12E8, C10E5, C8E4, OPOE and C12E7); Fos cholines (FC12 and FC14); Cymals (Cymal 4, Cymal 5 and Cymal 6); Neopentylglycols
(LMNG, DMNG and OGNG); Amine oxides (LDAO and DDAO); Zwittergent (SB-3 14 and SB-3 12); Mixed (Mixed detergents).
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Appendix A. Supplementary data
Supplementary data associated with this article can be found, in the
online version, at http://dx.doi.org/10.1016/j.ymeth.2018.04.009.
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